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Population Pharmacokinetics of Terizidone and Cycloserine in 
Patients with Drug-resistant Tuberculosis 
Mwila Mulubwa – 2019 
Introduction: Drug-resistant tuberculosis remains a major world health problem and 
one of the leading cause of death worldwide. Despite adequate adherence to anti-
tuberculosis drugs by patients, the emergence of drug-resistance tuberculosis still 
occurs. This fact implies other factors leading to the emergence of resistant strains of 
Mycobacterium tuberculosis. A multidrug treatment regimen, which may consist of five 
to seven different drugs including terizidone, is used in the treatment of drug-
resistance tuberculosis. Terizidone is part of the multidrug regimen whose 
pharmacokinetics is scarce in literature and plasma concentration profile unknown. 
Two molecules of cycloserine joined by terephtalaldehyde moiety makes up a 
molecule of terizidone, which is thought to undergo complete metabolism into 
cycloserine in vivo. Additionally, the current literature report that terizidone and 
cycloserine can be used interchangeably as they are thought to be equivalent. The 
aim of this thesis was first to develop and validate bioanalytical methods for 
determination of terizidone and cycloserine in patients’ plasma samples. Secondly, to 
model population pharmacokinetics of terizidone and cycloserine. Thirdly, to 
determine the amount of cycloserine resulting from metabolism of terizidone. 
Methods: This was a non-randomised prospective clinical study involving 39 patients 
with drug-resistant tuberculosis admitted to Breweskloof Hospital for intensive 
treatment phase. All patients took 500 – 750 mg daily dose of terizidone in addition to 
other anti-tuberculosis drugs. Blood was sampled at pre-dose, 0.5, 1, 2, 3, 3.5, 4, 8, 
16 and 24 hours post terizidone administration. Chromatographic bioanalytical 
methods for determination of both terizidone and cycloserine in plasma samples were 
developed and validated. Terizidone population pharmacokinetics was modelled 
solely and jointly with cyloserine using nonlinear mixed-effects modelling implemented 
in Monolix 2018R1 software. The R statistical software version 3.5.2 was used to  
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perform correlation and regression analyses between secondary pharmacokinetic 
parameters of cycloserine and markers of hepatic function. 
Results: The HPLC-UV and UPLC-MS/MS methods were developed and validated 
for analysis of terizidone and cycloserine in patients’ plasma samples. A one-
compartment model with first-order elimination process described best the 
pharmacokinetics of terizidone. The absorption process was well characterised by a 
modified transit compartment model with mean transit time (MTT) and absorption rate 
constant (ka) of 1.7 h and 2.97 h-1, respectively. Albumin had significant effect on the 
apparent distribution volume (Vp/F) of terizidone (13.4 L). The total terizidone apparent 
clearance (Cltot/F) was 0.51 L/h. In the joint model, the percentage of the total amount 
of terizidone in the body that was metabolised to cycloserine was 29%. The clearance 
of terizidone via biotransformation and other routes was 0.47 and 0.1 L/h, respectively. 
The apparent clearance of cycloserine was 2.94 L/h and a one-compartment model 
with first-order elimination characterised well its pharmacokinetics. The median and 
range of cycloserine amount resulting from terizidone metabolism was 51.6 (0.64 – 
374) mg. Cycloserine Cmin and Cmax was significantly associated with increased 
conjugated bilirubin concentration (p < 0.05). Cmax was significantly associated with 
increased binding affinity of unconjugated bilirubin to albumin (p = 0.048). 
Conclusions: In this thesis, the population pharmacokinetics of terizidone and 
cycloserine, has for the first time, been described in patients with drug-resistant 
tuberculosis. The Vp/F in patients with drug-resistant tuberculosis is influenced by 
albumin concentration, which may affect drug concentration in patients with hepatic 
impairment. Terizidone and cycloserine is not interchangeable as the amount of 
cycloserine emanating from metabolism of terizidone is far lower than expected. 
Cycloserine plasma exposure may be a predisposing factor to the development of 
hyperbilirubinemia because of its relationship with conjugated bilirubin.  
Keywords: Terizidone, Cycloserine, Population pharmacokinetics, Drug-resistant 
tuberculosis, Metabolism.
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Chapter One 
 
1.0 BACKGROUND 
Tuberculosis, an infectious disease caused by the bacillus Mycobacterium 
tuberculosis remains a major world health problem. Respiratory tuberculosis is the 
active infection of the lungs, mediastinal lymph nodes, larynx or pleural cavity. It is 
typically spread by droplets from infected person particularly by coughing, sneezing, 
talking and breathing. The extra pulmonary tuberculosis affects any other organ. 
Pulmonary tuberculosis infection is of particular importance, as it is highly contagious 
and life threatening to affected patients. Extra pulmonary tuberculosis is less common 
and not very contagious (Gordon, Mwandumba, 2008).  
Each year, millions of people continue to fall sick with tuberculosis, which is one of the 
top ten causes of death in the world. Worldwide, an estimated 10 million people in 
2017 developed tuberculosis disease of which 90% were adults aged above 15 years 
(World Health Organization, 2018). In 2017, tuberculosis caused an estimated 1.6 
million deaths among HIV infected and uninfected patients (World Health 
Organization, 2018). Meanwhile, in 2015 tuberculosis morbidity was 10.4 million new 
cases while mortality was at 1.4 million deaths in addition to 0.4 million deaths patients 
co-infected with HIV (World Health Organization, 2016a). HIV infection is the most 
potent risk factor for active tuberculosis as it is directly related to the patient’s degree 
of immunosuppression. Hence, tuberculosis is common among HIV-infected persons 
worldwide. In some African countries, the rate of HIV infection among tuberculosis 
patients reaches 70–80% (World Health Organization, 2014, Longo et al., 2013). Not 
only does HIV infection increase the number of tuberculosis cases, but also changes 
the clinical course of tuberculosis (NDoH, 2014). 
The World Health Organization recommends a standardised first-line daily treatment 
regimen for new patients presumed or known to have drug-susceptible tuberculosis. 
The regimen consists of four drugs; isoniazid, rifampicin, pyrazinamide and 
ethambutol  which are taken in the initial phase or first two months of treatment 
http://etd.uwc.ac.za/
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followed by isoniazid and rifampicin in the continuation phase or the last four months 
(World Health Organization, 2010).  
Improper use of anti-tuberculosis drugs, among other factors have led to the 
emergence of drug resistant strains of Mycobacterium tuberculosis. It is estimated 
globally that 3.5% of new tuberculosis cases and 18% of previously treated cases have 
drug-resistant tuberculosis (World Health Organization, 2018).  
In South Africa, the design of standardised second-line regimen is based on first-line 
drug susceptibility testing at diagnosis. The drug-resistant tuberculosis treatment 
regimen for the intensive phase consists of kanamycin or amikacin (injection), 
moxifloxacin, ethionamide, terizidone, ethambutol and pyrazinamide. Isoniazid is 
added to the treatment for rifampicin mono-resistant tuberculosis patients. The 
continuation phase treatment comprises four drugs; terizidone, moxifloxacin, 
ethionamide and pyrazinamide which are administered daily (NDoH, 2013). The South 
African department of health has simplified the administration of standardised second-
line regimen across four weight bands; <33 kg, 33–50 kg, 51–70 kg and >70 kg in 
order to accommodate the fixed dose formulations that are available in the country 
(NDoH, 2013). 
The knowledge and subsequent application of pharmacokinetic information of anti-
tuberculosis drugs in the clinical management of tuberculosis is crucial in order to 
achieve the desired treatment outcomes (Savic et al., 2017). Characterisation of 
pharmacokinetic parameters of each anti-tuberculosis drug in the regimen is 
indispensable in order to determine appropriate optimal dose (Chirehwa et al., 2017).  
In additional to maximising the anti-mycobacterial efficacy, pharmacokinetic 
characterisation of anti-tuberculosis drugs ensures prevention of drug resistance with 
minimal toxicity (Srivastava et al., 2017, Savic et al., 2017). Terizidone and cycloserine 
(metabolite) are among the drugs used in the treatment of drug-resistant tuberculosis 
whose pharmacokinetics have not been extensively studied. 
1.1 PROBLEM STATEMENT 
Drug-resistant tuberculosis constitutes a major threat to the management of 
tuberculosis worldwide and remains a public health crisis. Its treatment success 
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globally is low, at 55% (World Health Organization, 2016a, World Health Organization, 
2018). 
In South Africa, drug-resistant tuberculosis has reached alarming proportions. It is 
estimated that 9.6% of all tuberculosis cases in South Africa are drug-resistant, 
thereby ranking it as one of the 30 high drug-resistant tuberculosis burden countries 
in the world (Streicher et al., 2012). A high proportion of drug-resistant tuberculosis 
cases in South Africa had unfavourable treatment outcome, with rates in the range 41-
58%. Additionally, treatment is empiric owing to a delay in Drug Susceptibility Tests 
results for second-line anti- tuberculosis drugs (NDoH, 2013, Brust et al., 2010). This 
phenomenon may partly explain the high mortality and low culture conversion rates 
reported in South Africa (Streicher et al., 2012). Drug-resistant tuberculosis is often 
associated with higher mortality rates in HIV-infected than uninfected patients (Brust 
et al., 2010, Streicher et al., 2012).  
Treatment of drug-resistant tuberculosis in HIV-infected patients remains a challenge 
(Isaakidis et al., 2012).The most common risk factors of anti-tuberculosis drug-
resistance are low plasma drug exposure due to drug-drug interactions, altered 
pharmacokinetics, inter-individual pharmacokinetic variability and inadequate dose or 
dosing frequency in drug-resistant tuberculosis patients co-infected with HIV (Alsultan, 
Peloquin, 2014, Satti, McLaughlin & Seung, 2013, Sotgiu et al., 2015).  
The pharmacokinetics of terizidone, which is one of the second-line drugs used in 
drug-resistant tuberculosis, is poorly described in literature (World Health 
Organization, 2015). The recommended daily dose of terizidone is 750 mg within the 
weight band of 33-70 kg for both intensive and continuous phases of treatment (NDoH, 
2013) but the average Cmax and Tmax is unknown. Furthermore, the primary parameters 
that describe terizidone pharmacokinetics at steady-state in drug-resistant 
tuberculosis patients and the sources of pharmacokinetic variability are unknown. 
Additionally, whether the 750 mg daily dose of terizidone is sufficient to guarantee 
adequate cycloserine exposure within the recommended target plasma range of 20–
30 µg/ml (Lange et al., 2014) is not established.  
The World Health Organization acknowledges a number of gaps in the current 
knowledge about the treatment of drug-resistant tuberculosis. Hence, population 
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pharmacokinetic studies aimed at determination of optimal drug dosing and safety is 
one of the research priorities in order to close these gaps (World Health Organization, 
2016b). Thus, attending to the urgent need for improved care and treatment of patients 
with drug-resistant tuberculosis (World Health Organization, 2018). Therefore, the 
study of the population pharmacokinetics of terizidone and cycloserine is highly called 
for. 
1.2 RESEARCH QUESTIONS 
1. What is the best population pharmacokinetic model that describes the fate 
of terizidone and its metabolite cycloserine in drug-resistant tuberculosis 
patients? 
2. What is the effect of HIV status on terizidone and cycloserine 
pharmacokinetic parameters?  
3. What are the sources and correlates of variability in terizidone and 
cycloserine plasma concentrations at recommended doses of terizidone? 
4. What are the clinically significant covariates influencing pharmacokinetic 
parameters of terizidone and cycloserine? 
5. How much cycloserine is formed from terizidone metabolism in patients with 
drug-resistant tuberculosis? 
1.3 GENERAL OBJECTIVE 
The general objective of this study was to describe the steady-state population 
pharmacokinetics of terizidone and cycloserine in drug-resistant tuberculosis patients 
with and without HIV infection. 
1.3.1 Specific objectives 
1. To develop and validate a high-performance liquid chromatography method 
coupled with ultraviolet detection (HPLC-UV) for determination of terizidone 
in plasma. 
2. To develop and validate a sensitive ultra-performance liquid 
chromatography tandem mass spectrometry (UPLC-MS/MS) method for 
determination of cycloserine in plasma.  
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3. To determine the plasma concentrations of terizidone and cycloserine in 
plasma of patients with drug-resistant tuberculosis. 
4. To model population pharmacokinetics of terizidone and its metabolite 
cycloserine in patients with drug-resistant tuberculosis. 
5. To determine the factors influencing the pharmacokinetics of terizidone and 
cycloserine in patients with drug-resistant tuberculosis.  
6. To determine the cycloserine amount emanating from terizidone 
metabolism in patients with drug-resistant tuberculosis. 
1.4 THESIS OUTLINE 
The thesis comprises nine chapters. Each chapter has its own reference list provided 
at the end. The chapters are arranged as follows: 
Chapter 1: Introduction 
Chapter 2: Literature review 
Chapter 3: Methodology 
Chapter 4: Analysis of terizidone in plasma using HPLC‐UV method and its 
application in a pharmacokinetic study of patients with drug-resistant 
tuberculosis. 
Chapter 5: Sensitive ultra-performance liquid chromatography tandem mass 
spectrometry method for determination of cycloserine in plasma for a 
pharmacokinetics study. 
Chapter 6: Steady-state population pharmacokinetics of terizidone and its 
metabolite cycloserine in patients with drug-resistant tuberculosis. 
Chapter 7: Amount of cycloserine emanating from terizidone metabolism and 
relationship with hepatic function in patients with drug-resistant 
tuberculosis. 
Chapter 8: General discussion  
Chapter 9: Overall conclusions
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Chapter Two 
 
2.0 INTRODUCTION 
The purpose of this chapter is to review the current literature on the clinical 
pharmacology (pharmacokinetics/pharmacodynamics) of terizidone and cycloserine in 
human subjects. Each sub-section ends with a brief summary. The bioanalytical 
methods for determination of terizidone and cycloserine in plasma are reviewed. 
Furthermore, factors that influence the pharmacokinetics of these drugs are reviewed 
in subsequent sections. On the other hand, the link between pharmacokinetics and 
the development of drug-resistant tuberculosis is discussed in light of other drugs used 
in tuberculosis treatment. In general, the relationship between plasma exposure (AUC, 
Cmax) of several anti-tuberculosis drugs and outcomes (efficacy) is illustrated. 
Therefore, the role that pharmacokinetics play in the management of tuberculosis is 
justified. In addition, the concept of dose optimisation of anti-tuberculosis drugs 
performed in some studies is substantiated. In order to emphasise the role of 
pharmacokinetics in tuberculosis management, methods for optimal dose 
determination such as pharmacokinetic modelling and simulation are presented with 
applicable studies reviewed. The need for terizidone dose optimisation based on 
pharmacokinetic target is dealt with. Finally, the chapter is summarised by highlighting 
the current gaps in the pharmacokinetics knowledge of terizidone and its metabolite 
cycloserine. 
2.1 QUANTIFICATION OF TERIZIDONE AND CYCLOSERINE IN PLASMA 
Quantification of terizidone in plasma has only been achieved using colorimetric 
method (Zitkova, Toušek, 1974). In this method, an analyte of interest undergoes a 
chemical reaction with another reactant to form a coloured target chemical product. 
The intensity of the target coloured chemical product or its optical absorbance, which 
is measured using light with suitable wavelength, is proportional to the concentration 
of the analyte (Dubois et al., 1956). However, the current standard bioanalytical 
method employed in clinical pharmacokinetic studies is a chromatographic method 
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(USFDA, 2013, ICH, 2005). Chromatography is among the most versatile analytical 
techniques used to separate and quantify complex mixtures based on some 
compound’s properties such as polarity, molecular weight, particle size, solubility and 
ionic mobility (Robards et al., 1994). To date, no chromatographic bioanalytical 
method has been employed to determine plasma concentrations of terizidone.  
Unlike terizidone, chromatographic methods for determination of cycloserine in 
plasma have been employed before (Polagani et al., 2013, Patel et al., 2011, Mao et 
al., 2017, Yaroshenko, Grigoriev & Sidorova, 2014, Stepanova et al., 2016, Supriya, 
Ashish & Meena, 2012). However, the steps involved in the sample preparations are 
many making the routine analysis of plasma samples to be prone to imprecision and 
inaccuracy. 
2.2 CLINICAL PHARMACOLOGY OF TERIZIDONE  
Terizidone is categorised as group IV anti-tuberculosis drug by the World Health 
Organization and classified as a second-line drug. It is effective against 
Mycobacterium tuberculosis, used in the treatment of both pulmonary and extra 
pulmonary tuberculosis, and reserved for treatment of drug-resistant tuberculosis 
(World Health Organization, 2014). It is a dimer which is obtained by combining two 
molecules of cycloserine and one molecule of terephtalaldehyde (Figure 1). Terizidone 
and cycloserine have advantage over other drugs in that they do not show cross-
resistance with other active anti-tuberculosis drug classes (NDoH, 2013). The World 
Health Organization Prequalification Team-Medicines states that terizidone is not 
detected in plasma using a bioanalytical method with a Lower Limit of Quantification 
of 0.2 μg/mL and appears to be pre-systemically hydrolysed completely into its active 
metabolite cycloserine (World Health Organization, 2015). 
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Figure 1. Terizidone molecule (A) and cycloserine molecule (B). 
2.2.1  Terizidone pharmacokinetics 
The pharmacokinetic properties of terizidone are scarce and poorly described in the 
literature. Currently, no pharmacokinetic studies of the drug have been performed in 
patients with drug-resistant tuberculosis. The drug was developed in the 1970s when 
the bio-analytical methods were limited (World Health Organization, 2015). Plasma 
concentration of terizidone in these pharmacokinetic studies (Zitkova, Toušek, 1974, 
Zitkova et al., 1983) was quantified using colorimetric method, which is unspecific and 
currently not in use. 
Terizidone is rapidly absorbed after single oral administration of 250-750 mg dose on 
empty stomach (Table1) and reaches maximum concentration (Cmax) in 2-4 hours. 
Absorption shows some dependence on age. Doses above 500mg do not cause a 
proportional increase in the concentration (Vora, 2010, Zitkova, Toušek, 1974).  
It is widely distributed and the volume of distribution (V/F) increases with increasing 
dose. Terizidone has a low elimination rate constant, clearance and long half-life. 
Clearance ranges from 2.49-6.4 L/h over the dose range of 250-750mg (Zitkova, 
Toušek, 1974, Zitkova et al., 1983). 
Thirty nine per cent of the administered dose is excreted in urine after 30 hours. The 
high concentrations of terizidone in urine indicate the possibility of using it in 
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genitourinary tuberculosis (Kottász, Babics, 1972). The urine excretion of terizidone in 
adults is slower than in young ones.  
It is, however, worthy to note the significant shortcoming in Zitkova and Toušek 
(Zitkova, Toušek, 1974) study design. Blood sampling was not done at steady-state 
but it was performed on the first day of the trial after administration of a single dose. 
In order to reach steady-state, it takes about four to five elimination half-lives. The 
authors used an open one-compartment model to calculate the pharmacokinetic 
parameters of terizidone. Based on visual inspection of the concentration-time curves, 
rough estimates for and the observed average Cmax were 8, 17 and 19 µg/mL following 
administration of 250, 500 and 750 mg single doses of terizidone, respectively   
(Zitkova, Toušek, 1974). However, simulations of one-compartment model using MlxR 
package of R software (R Core Team, 2018) with average pharmacokinetic 
parameters shown in Table1 yielded lower Cmax but same Tmax. The simulated Cmax for 
250, 500 and 750 mg single doses were 2.1, 2.6 and 2.8 µg/mL, respectively. Either 
this huge difference between the observed and simulated Cmax of terizidone imply that 
pharmacokinetic parameters were incorrectly estimated or the model used to describe 
the pharmacokinetics was inappropriate. Therefore, the pharmacokinetic parameters 
of terizidone published in literature (Zitkova, Toušek, 1974) may be incorrect.   
Table1: Pharmacokinetic parameters of terizidone in tuberculosis patients 
N Dose 
(mg) 
ka (h-1) V/F 
(L) 
Cl/F 
(L/h) 
ke (h-1) T1/2 (h) Tmax 
(h) 
Source 
10 250 1.36 112.6 2.49 0.022 33 3 (Zitkova, Toušek, 1974) 
15 500 1.39 175.1 6.30 0.035 21 3 (Zitkova, Toušek, 1974) 
10 750 1.17 245.6 6.40 0.028 24.8 3 (Zitkova, Toušek, 1974) 
2.2.2  Terizidone pharmacodynamics 
The mode of action of terizidone is similar to that of cyloserine. Its bacteriostatic effect 
is achieved through inhibition of cell wall synthesis by competitively inhibiting L-alanine 
racemase and D-alanine ligase, thereby impairing peptidoglycan formation needed for 
Mycobacterium tuberculosis cell wall synthesis. The minimum inhibitory concentration 
(MIC) ranges from 4-130 mg/mL in susceptible strains (Vora, 2010). Currently, there 
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is no information on the MIC of terizidone in drug-resistant strains. Therefore, the 
pharmacodynamics indices such as Cmax/MIC ratio, AUC/MIC ratio and time > MIC 
(Craig, 2007) which are used to link anti-infective drug exposure and response are not 
available for terizidone. 
Prior to the 1970s, some clinical studies were performed in tuberculosis patients 
mainly on terizidone safety and tolerability. However, literature that described these 
studies was in Portuguese, Italian, Croatian and Russian that were reviewed by 
Hwang et al (Hwang et al., 2013). The adverse effects profile of terizidone is similar to 
that of cycloserine but terizidone is better tolerated and hence leads to better 
compliance. The few reported side effects are slurred speech, dizziness, headache 
and convulsions. Others adverse effects reported include depression, tremors, 
insomnia, confusion and suicidal tendency (Vora, 2010). The electroencephalographic 
studies using light and sonic stimulation show that terizidone leads to less activating 
effect of the ascending part of the reticular formation of the brain stem than 
cycloserine. Patients with concomitant psycho-neurological impairments tolerate well 
terizidone dose of 250 mg taken eight hourly (Shmelev, Shabalova & Kolosovskaia, 
1975). 
2.2.3  Factors influencing pharmacokinetics of terizidone 
There are scanty studies that have established the factors that affect the 
pharmacokinetics of terizidone, if any. The only study trial that was performed in the 
1970s found urine excretion of terizidone lower in older tuberculosis patients than in 
young ones. Thus, old age was found to be affecting the renal excretion of the drug 
(Zitkova, Toušek, 1974). This could have been due to the decrease in both renal 
function and high transaminase levels which were significantly worse in elderly 
patients than the young ones (Zitkova, Toušek, 1974). These authors did not develop 
mixed effects pharmacokinetic model that could have accounted for the effects of other 
covariates on pharmacokinetics of terizidone. It is however, worthy to note that Zitkova 
and Toušek carried out their study in an era before the concept of population 
pharmacokinetics (non-linear mixed effects modelling) was introduced in the 
pharmacokinetics discipline (Sheiner, Rosenberg & Marathe, 1977). 
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2.3 CLINICAL PHARMACOLOGY OF CYCLOSERINE 
Cycloserine is an analogue of D-alanine amino acid and a broad-spectrum antibiotic 
used in combination with other drugs (Brennan, Young & Robertson, 2008). The World 
Health Organization classifies it as a group 4 oral bacteriostatic drug used as the 
second-line treatment for drug-resistant tuberculosis (World Health Organization, 
2014). Depending on the concentration, cycloserine may also be bactericidal on 
particular strains (Brennan, Young & Robertson, 2008). 
2.3.1  Cycloserine pharmacokinetics 
The pharmacokinetics of cycloserine in drug-sensitive and –resistant tuberculosis 
patients is very limited while there are currently no pharmacokinetic studies performed 
in HIV-infected patients receiving anti-retroviral therapy.  
In patients with drug-sensitive tuberculosis, oral doses of 250 – 750 mg of cycloserine 
reach maximum concentration in blood within 2-3 hours (Table 2).The rate of 
absorption in drug-resistant tuberculosis patients is slower than in drug-sensitive 
tuberculosis, with absorption rate constant of 0.135 versus 1.67 ± 0.25 (Chang et al., 
2017, Zitkova, Toušek, 1974). 
The rate of absorption in healthy subjects is faster than in tuberculosis patients. 
Meanwhile, in healthy subjects, a single dose of cycloserine is rapidly absorbed and 
reaches peak plasma concentration in approximately 0.84 hours after oral 
administration of 250 – 100 mg. A fatty meal or orange juice increases the Tmax in 
healthy subjects but the extent of cycloserine absorption is not affected. In fasting state 
of healthy subjects, cycloserine has lag time of 0.4 hours (Zitkova, Toušek, 1974, Zhou 
et al., 2015). The Cmax after a dose of 500 mg and 250 mg ranges between 12.4 – 42.9 
µg/mL 7.21 – 30 µg/mL, respectively (Brennan, Young & Robertson, 2008, Zhou et al., 
2015, Zhu et al., 2001, Zheng-sheng et al., 2014). However, Cmax in drug-resistant 
tuberculosis patients has not yet been reported in literature. The concentration of 
cycloserine in cerebrospinal fluid of tuberculosis patients after a dose of 250 mg 
reaches maximum concentration of 12.8 µg/mL in 2 hours (Holdiness, 1985). 
Cycloserine is widely distributed to most body fluids and tissues, including cerebral 
spinal fluid, lymph tissue, breast milk, lungs, bile, sputum, pleural, synovial fluids and 
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crosses the placental barrier. The concentration reached in cerebrospinal fluid is 79% 
of the serum concentration (Brennan, Young & Robertson, 2008, Holdiness, 1985). 
The V/F in drug-sensitive tuberculosis patients is higher than in healthy subjects, 115-
255 L and 15.2-16.8 L, respectively (Zitkova, Toušek, 1974, Zhou et al., 2015). The 
clearance is higher in tuberculosis patients than in healthy subjects, 3.2 - 8.6 L/h and 
0.91-1.1 L/h, respectively. In drug-resistant tuberculosis patients, the V/F is 
surprisingly comparable to that in healthy subjects (Table 2). The pharmacokinetic 
properties of cycloserine are linear at doses ranging from 250-1000 mg in healthy 
subjects (Zitkova, Toušek, 1974, Zhou et al., 2015). 
Excretion is primarily renal, with 38-70% excreted unchanged within 12 to 30 hours 
(Brennan, Young & Robertson, 2008, Zitkova, Toušek, 1974). 
Critical review of the study by Zitkova and Toušek (Zitkova, Toušek, 1974) show some 
flaws in the estimated pharmacokinetic parameters. Simulations of Cmax using the 
pharmacokinetic model, which the authors used to estimate the pharmacokinetic 
parameters of cycloserine, yielded very low values compared to the observed Cmax. 
The simulated Cmax at single doses of 250, 500 and 750 mg yielded 2.01, 2.51 and 
2.73 µg/mL compared with 8, 14 and 17 µg/mL observed average Cmax, respectively. 
The simulated Tmax was equally different from the observed one except for the 750 mg 
dose which was same as the observed one. Therefore, the pharmacokinetic 
parameters of cycloserine, which Zitkova and Toušek estimated, may be incorrect and 
this could be the reason why they seem to be different from the rest of other studies 
shown in Table 2. 
Furthermore, terizidone and cycloserine were co-administered in this study and hence 
there was also cycloserine emanating from hydrolysis (metabolism) of terizidone which 
authors did not consider in their pharmacokinetic calculations. It is for this reason that 
the authors noted that increase in blood concentration of terizidone was not 
proportional to the two molecules of cycloserine that make up a molecule of terizidone 
even after administration of same dose of both drugs (Zitkova, Toušek, 1974). The 
sampling of blood for pharmacokinetic analyses in this study was not done at steady-
state. These factors highlighted above contributed to the inaccuracy of cycloserine 
pharmacokinetic parameters  
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Table 2. Pharmacokinetic parameters of cycloserine in tuberculosis patients and healthy volunteers 
aMedian value, bmean value, *AUC0-∞, †L/kg, ‡L/h/kg, cmeasured in cerebrospinal fluid.
Subjects N Dose 
(mg) 
Tlag 
(h) 
ka (h-1) V/F 
(L) 
Cl/F 
(L/h) 
T1/2 
(h) 
ke (h-1) Cmax 
(µg/mL) 
Tmax 
(h) 
AUC 
(µg•h/mL) 
Source 
TB patients 10 250  - 1.60 115 3.23 25 0.028 - 2 - (Zitkova, Toušek, 1974) 
 15 500 - 1.47 176.5 8.31 15.8 0.047 - 3 - (Zitkova, Toušek, 1974) 
 10 750  - 1.94 255.8 8.65 21.8 0.033 - 2 - (Zitkova, Toušek, 1974) 
 22 250 - - - - - - 12.8c 2c - (Holdiness, 1985) 
Drug-resistant 
TB 
14 250-500 
bd 
- 0.135 10.5 1.38 - - - - - (Chang et al., 2017) 
Healthy volunteers             
Fasting 12 500 0.4 3.97 0.41† 0.033‡ 8.26 0.083 14.8a 0.75 214* (Zhu et al., 2001) 
Fatty meal 12 500 - - - - - - 12.4a 3.5 217* (Zhu et al., 2001) 
Orange juice 12 500 - - - - - - 13.8a 1.5 225* (Zhu et al., 2001) 
Anti-acid 12 500 - - - - - - 19.2a 0.88 216* (Zhou et al., 2015) 
 12 250 - - 16.82 1.11 12.33 - 19.42b 0.86 283* (Zhou et al., 2015) 
 12 500 - - 15.26 0.91 13.27 - 42.9b 0.83 643* (Zhou et al., 2015) 
 12 1000 - - 16.61 0.99 13.13 - 84.76b 0.84 1224* (Zhou et al., 2015) 
 16 250 bd - - 10.7 1.2 20.3 - 24.9 4 242.3 (Park et al., 2015) 
Fatty meal 10 250 - - - - 11.4 - 9.56 1.8 135* (Zheng-sheng et al., 2014) 
Fasting 10 250 - - - - 12.5 - 7.21 2.8 125* (Zheng-sheng et al., 2014) 
 - 250 bd - - - - 10 - 25-30 - - (Brennan, Young & 
Robertson, 2008) 
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2.3.2  Cycloserine pharmacodynamics 
Cycloserine achieves bacteriostatic effect by inhibiting alanine racemase and d-
alanine ligase which are both essential enzymes for the synthesis of peptidoglycan 
and subsequently cell-wall biosynthesis and maintenance. It has in vitro potency 
against Mycobacterium tuberculosis with MIC ranging from 6.2-25 µg/mL and depends 
on the media used, pH and the presence of d-alanine which inhibits its activity. 
Cycloserine can be bacteriostatic or bactericidal depending on local concentration 
effects along with efficacy against the particular bacteria strain involved. About <1log 
(80%) of mycobacterium tuberculosis is killed in macrophages with cycloserine plasma 
concentration of 50 µg/mL (Brennan, Young & Robertson, 2008, Peloquin, 2008). 
The Cmax/MIC ratio of 1.7 is achieved after a daily dose of 500 mg cycloserine at 
steady-state. A dose of 500 mg every 12 hours at steady-state results in Cmax/MIC 
ratio of about 2.4 and 24-hour-concentration/MIC ratios of about 1. The time in which 
the cycloserine serum concentrations exceed the MIC is about 8 hours. However, 
the precise cycloserine pharmacodynamic index that requires optimisation is not 
known (Berning, Peloquin, 1999). The target Cmax range after 250-500 mg doses is 
20-35 µg/mL. For therapeutic drug monitoring, a dose increase is recommended if 
the Cmax is less than 15 μg/mL also a dose decrease if the Cmax is above 40 μg/mL 
(Alsultan, Peloquin, 2014, Peloquin, 2002). 
The main adverse effect of cycloserine is central nervous system (CNS) toxicity which 
includes depression, dizziness, hyper-excitability, memory loss, lethargy, anxiety and 
confusion. The CNS effects may be worse with plasma concentrations greater than 35 
μg/mL. The lethargy is often seen at normal plasma concentrations (Peloquin, 2008). 
2.3.3  Factors influencing pharmacokinetics of cycloserine  
In health individuals, high fat meal lowers the Cmax, delay the Tmax, decrease the ka 
and increase the absorption half-life but does not affect AUC0-∞. The orange juice or 
anti-acids (aluminium hydroxide or magnesium hydroxide) does not significantly affect 
cycloserine disposition (Zheng-sheng et al., 2014, Zhu et al., 2001). 
Gender in health subjects affects Cl/F and elimination half-life. The Cl/F is greater in 
women than in men while half-life in men is longer than in women (Zhou et al., 2015). 
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Meanwhile, in drug-resistant tuberculosis patients, only one study investigated the 
effects of covariates on cycloserine ka, Cl/F and V/F. The covariates such as age, sex, 
body weight, body mass index, serum albumin and serum creatinine did not have any 
effect on ka, Cl/F and V/F (Chang et al., 2017). There was however, interindividual 
variability in Cl/F and V/F of 22.3% and 35.1%, which could not be accounted for by 
any covariate investigated (Chang et al., 2017). In this study, the influence of HIV 
infection and antiretroviral therapy on pharmacokinetic parameters of cycloserine was 
not investigated. 
Generally, pharmacokinetic variability is affected by: 
 Pathophysiologic and physiologic factors such as renal and hepatic impairment, 
co-morbidities (other disease states) and pregnancy.  
 Environmental factors that include exposure to pollutants, diet and smoking.  
 Drug–drug interactions,  
 Genetic phenotypes that affect the clearance of drugs through hepatic 
metabolism by polymorphic cytochrome P450 isoforms such as CYP2D6, 
2C19, 2C9 and 2A6.  
 Other factors such as circadian rhythm, adherence, food effect and the timing 
of meals, activity and posture (Ette, Williams, 2004). 
2.4 ANTI-MYCOBACTERIAL PHARMACODYNAMICS AND REGIMEN 
EFFICACY 
Pharmacodynamics relates the time course of pharmacokinetics or plasma drug levels 
to the therapeutic action or toxicological effects. For antimicrobials, it describes the 
relationship that exist between the plasma drug concentration to which the bacteria is 
exposed at various sites of infection and bacterial killing (David, Willian, 2005). The 
major parameters that have been used to measure in vitro activity of antimicrobials 
against various bacteria are MIC and minimum bactericidal concentration (MBC). Even 
though MIC and MBC are excellent predictors of the potency of an antimicrobial agent, 
they do not provide information on the time course of antimicrobial activity (Craig, 
2007). Using the MIC as a measure of the potency of drug-organism interactions, the 
pharmacokinetic parameters that determine efficacy such as Cmax and AUC can be 
converted to pharmacokinetic/pharmacodynamics (PK/PD) indices. The Cmax/MIC and 
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AUC/MIC ratios have been the PK/PD parameters that correlate well with in vivo 
efficacy for concentration dependent killing anti-tuberculosis drugs. Time above MIC 
(T>MIC) is the PK/PD parameter for anti-tuberculosis drug that exhibit time dependent 
killing (Craig, 2007). 
Some proteins have been proposed as surrogate biomarkers of anti-tuberculosis 
treatment response. The serum inducible protein of 10 kDa (IP-10) decreases 
significantly after anti-tuberculosis treatment. Therefore, it can be a useful marker for 
monitoring therapy and efficacy in patients with active tuberculosis (Hong et al., 2014). 
In drug-resistant tuberculosis patients, chemokines and acute inflammation markers 
[monocyte chemoattractant protein 1 (MCP-1), IP-10, soluble interleukin-2 receptor 
alpha (sIL-2Rα), serum amyloid A (SAA), C-reactive protein (CRP) and vascular 
endothelial growth factor A (VEGF-A)] predict the microbiological outcome and hence 
predictive of treatment response (Ferrian et al., 2017). No studies that have shown 
how pharmacokinetics of anti-tuberculosis drugs in drug-resistant tuberculosis 
patients are related to these biomarkers. However, it is undoubted that plasma 
exposure to anti-tuberculosis drugs (pharmacokinetics) plays a vital role since drug-
resistant strain induces the production of these chemokines (Basile et al., 2017) which 
correlate well with treatment outcome (Ferrian et al., 2017). 
In patients with pulmonary tuberculosis, conversion of sputum mycobacterial cultures 
from growth to negative growth of mycobacteria tuberculosis is considered the most 
important indicator of treatment response or efficacy of anti-tuberculosis 
pharmacologic treatment for drug-resistant tuberculosis (World Health Organization, 
2010b). From the literature, the sputum conversion at 2 or 3 months is taken as a good 
treatment response in pulmonary tuberculosis (Brust et al., 2011, Holtz et al., 2006, 
Kurbatova et al., 2012, Kwon et al., 2008, Yew et al., 2000). The efficacy of the second-
line regimen in drug-resistant tuberculosis patients whether HIV-infected or not, 
ranges between 24 – 85% in terms of the rate of sputum culture conversion. The 
median time to culture conversion ranges between 60 - 90 days (Brust et al., 2011, 
Holtz et al., 2006, Loveday et al., 2012, Kurbatova et al., 2012, Kwon et al., 2008, Yew 
et al., 2000). It is worthy to note that the efficacy in these studies was not related to 
the plasma concentration of each individual drug in the regimen. Therefore, variations 
in the efficacy could be a result of inadequate individual drug exposure. 
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There are, however other factors that influence the efficacy of the second-line anti-
tuberculosis regimen.  Factors such as baseline positive (Kurbatova et al., 2012) 
smear, smoking, previous use of second-line drugs, older age, male gender and 
bilateral radiological involvement (Mota et al., 2012, Qazi et al., 2011).  
2.5 MECHANISMS OF DRUG-RESISTANT TUBERCULOSIS  
Multidrug-resistant tuberculosis (MDR-TB) is defined as the infection with 
Mycobacteria tuberculosis strains which are resistant to rifampicin and isoniazid, the 
key first-line anti-tuberculosis drugs (Zumla et al., 2012). Drug resistance in 
tuberculosis is epidemiologically classified as primary, acquired and initial. Primary 
drug resistance occur in treatment naïve patients who get infected with resistant strain 
of bacteria. Acquired drug resistance applies to patients previously treated with drug 
susceptible tuberculosis and later become resistant to medications mainly due to non-
adherence or inappropriate/irregular treatment (Long, 2000). The sub-optimal drug 
therapy causes spontaneous mutations in the mycobacteria chromosomal genes that 
leads to production of resistant strains (Almeida Da Silva, Pedro Eduardo, Palomino, 
2011). Initial or mixed drug resistance is a combination of primary and acquired drug 
resistance as patients in this category have unconfirmed drug history although claim 
to be treatment naïve (Long, 2000). 
There are six genotypes of Mycobacterium tuberculosis strains that have been 
identified in MDR-TB patients in the Western Cape Province of South Africa. These 
are Beijing, Latin American and Mediterranean (LAM), Haarlem, X, Family 11(F11), 
Family 28 (F28) and IS6110 low copy number clades (Johnson et al., 2010, Marais et 
al., 2006, Streicher et al., 2004). Beijing is the most prevalent genotype family followed 
by LAM. Infection with either Beijing or Haarlem strain increases the likelihood to have 
drug resistant tuberculosis than other strain families (Marais et al., 2006). The Beijing 
cluster 220 genotypes with -15 inhAC-T promoter and rpoB gene mutations confer 
isoniazid and rifampicin resistance, respectively (Johnson et al., 2006).  
The action of rifampicin on Mycobacterium tuberculosis is bactericidal with MIC range 
of 0.05-10 µg/mL in different media. It targets the β-subunit of DNA dependent RNA 
polymerase and interferes with the synthesis of RNA (Zhang, Yew, 2009). The β-
subunit of the RNA polymerase is encoded in the 81 base pair region of rpoB gene. 
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Mutations in the rpoB gene (amino acid 507-533) are accountable for most rifampicin 
resistance and cross-resistance to other rifamycins (Laurenzo, Mousa, 2011, Zhang, 
Yew, 2009). Furthermore, mutations in codons 531 (S531L) and 526 (H526P/D/Y) give 
rise to high-level rifampicin resistance with MIC above 64 µg/mL (Laurenzo, Mousa, 
2011). 
Isoniazid is a prodrug that is activated by catalase peroxidase leading to production of 
multiple reactive species such as oxygen radicals and isonicotinic acyl radicals, which 
lead to the killing of Mycobacterium tuberculosis infected cells (Zhang, Yew, 2009). 
The enzyme, enoyl-acyl carrier protein reductase (InhA), involved in mycolic acid 
synthesis is thought to be the primary target of inhibition by isoniazid. Mutations in two 
genes KatG and InhA account for majority of isoniazid resistance as they result in loss 
of catalase peroxidase activity (Laurenzo, Mousa, 2011).  
2.5.1  Factors contributing to the development of drug-resistant tuberculosis 
Poor treatment outcome such as acquired drug-resistant tuberculosis are mainly 
caused by patient factors like non-adherence, inappropriate treatment regimen, 
inadequate supply of anti-tuberculosis drugs or supply of poor quality drugs (World 
Health Organization, 2014). Comorbidities and undernutrition may also cause 
malabsorption of anti-tuberculosis drugs leading to low bioavailability and sub-
therapeutic concentrations (Murray, Cohen, 2009, World Health Organization, 2014). 
Low exposure to anti-tuberculosis drugs or to a single drug because of inappropriate 
regimen or poor treatment adherence provides survival advantage for drug-resistant 
bacteria (Pablos-Mendez, Lessnau, 2000). Similarly, if new cases of tuberculosis are 
not successfully treated due to clinical mismanagement, result in the increase of drug-
resistant tuberculosis prevalence by ten-fold (Pablos-Mendez, Lessnau, 2000).  
Comorbidity like HIV infection was found to be associated with drug-resistance and 
resistance to any other drug even after adjusting for confounding effect of previous 
anti-tuberculosis therapy (Murray, Cohen, 2009). This is thought to occur because of 
non-adherence due to polypharmacy in HIV infected patients, overlapping toxicities 
and drug interactions between anti-tuberculosis and anti-retroviral drugs (Murray, 
Cohen, 2009). Drug-resistant tuberculosis has been associated with previous history 
of pulmonary tuberculosis and episodes and previous treatment with category 2 drugs 
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(streptomycin, kanamycin, amikacin and capreomycin) (Workicho, Kassahun & 
Alemseged, 2017, Dessalegn et al., 2016). Being younger than 30 years is associated 
with higher chance of having drug-resistant tuberculosis than being older. This could 
be due to non-adherence or reluctance in adhering to the anti-tuberculosis drugs in 
younger patients (Workicho, Kassahun & Alemseged, 2017). A case-control study 
found type II diabetes and past smoking status to be associated with drug-resistant 
tuberculosis (Rifat et al., 2014). In another study, diabetes mellitus was independently 
associated with drug resistance even after adjusting for other factors (Baghaei et al., 
2016). It is suggested that in type II diabetes, low immunity may enhance propensity 
to infection with resistant strains (Rifat et al., 2014). Consumption of alcohol and 
chronic anti-acid use were found to be significant predictors of drug-resistant 
tuberculosis (Mulisa et al., 2015). Furthermore, indulgence in both alcohol and tobacco 
influence the outcome of treatment with category 4 drugs in drug-resistant tuberculosis 
patients (Yadav et al., 2016). 
The factors that lead to development of drug-resistant tuberculosis are largely those 
that eventually result in low plasma exposure to anti-tuberculosis. These are non-
adherence, comorbidities, malabsorption and drug-drug interactions through the use 
of medication for comorbidities and social drugs such as tobacco and alcohol. Erratic 
supply of anti-tuberculosis and use of wrong treatment regimens ultimately lead to 
drug resistance resulting from inadequate drug exposure.  
2.6 THE ROLE OF PHARMACOKINETICS IN PREVENTION OF DRUG-
RESISTANT TUBERCULOSIS 
Despite the high rate of adherence to anti-tuberculosis medication by patients, 
emergence of drug-resistant tuberculosis still occur (Calver et al., 2010). 
Pharmacokinetic variability in anti-tuberculosis drugs is the more likely cause of the 
emergence of drug-resistant tuberculosis (Srivastava et al., 2011) since not only is 
associated with drug-resistant tuberculosis but also treatment failure (Pasipanodya, 
Srivastava & Gumbo, 2012).  
2.6.1  Relationship between drug exposure and tuberculosis treatment outcome 
Rifabutin AUC0-24 and median Cmax were found significantly lower in patients who had 
acquired rifampicin resistance (ARR) than those who did not. Subsequent adjusted 
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analyses showed that rifabutin AUC0-24 of less than 4.5 mg*h/mL was associated with 
relapse or failure (Weiner et al., 2005). Isoniazid median AUC0-12 was also significantly 
lower in patients with relapse or ARR failure (Weiner et al., 2005). A controlled trial 
revealed a strong association between isoniazid AUC0-12 and treatment failure or 
relapse while Cmax did not show any association (Weiner et al., 2003). The AUC0-12 
was significantly lower among patients with relapse or failure. The trial on the contrary 
did not find any significant associations between rifampin AUC (or Cmax) and treatment 
outcome (Weiner et al., 2003). The time over a certain concentration threshold as 
described by AUC is the better determinant pharmacokinetic parameter for treatment 
outcome of isoniazid than Cmax. 
In drug-sensitive tuberculosis, the 24-hour AUCs for isoniazid, rifampicin and 
pyrazinamide were found to be most predictive of long-term outcomes (relapse, 
treatment failure and death). Furthermore, target plasma concentrations of these 
drugs were not associated with long-term outcomes (Pasipanodya et al., 2013). Only 
pyrazinamide peak concentration was found the highest predictor of 2-month sputum 
conversion and sterilizing activity (Pasipanodya et al., 2013). Another study showed 
that standard dosing of rifampin resulted in sub-therapeutic plasma levels and poor 
clinical response. Dose increase resulted in improved clinical outcome with no change 
in side effects profile (Mehta et al., 2001). 
Lower than expected Cmax values of ethambutol, rifampin and isoniazid occurred 
frequently in a cohort of tuberculosis patients (Chideya et al., 2009). Meanwhile, poor 
tuberculosis treatment outcome was associated with low pyrazinamide Cmax and more 
frequently among HIV-infected patients with a CD4 cell count of less than 200 cells/mL 
(Chideya et al., 2009). Surprisingly, in HIV negative patients, sub-therapeutic plasma 
levels of ethambutol, isoniazid, rifampicin and ofloxacin sampled at 1-2 hours were 
reported (Kimerling et al., 1998). Additionally, improvement in the clinical outcomes 
was noted after drug doses were adjusted upwards. Drug interactions and 
malabsorption could not be ruled out as probable reason since patients were reported 
to be smokers, alcohol and laxative abusers (Kimerling et al., 1998).  
On the contrary, one study revealed that despite the presence of low concentrations 
of rifampicin, isoniazid and pyrazinamide in the patients, treatment response was good 
(Burhan et al., 2013). There was no any association found between plasma 
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concentrations and sputum culture results at four and eight weeks (Burhan et al., 
2013). However, this study assessed only two time points and this could have led to 
the underestimation of the Cmax especially in the presence of delayed drug absorption. 
Similarly, despite a substantial number of drug-resistant tuberculosis patients not 
achieving the minimum therapeutic concentrations of cycloserine, moxifloxacin and 
prothionamide, the sputum conversion after two months of therapy was not affected 
(Lee et al., 2015). These concentrations, nevertheless, may have not represented the 
typical Cmax as each patient sample was drawn between 2 to 6 hours (Lee et al., 2015). 
Another reason for this observation is that the authors could not use AUC as the 
predictor of sputum conversion as their study design could not allow. In another study, 
lower than recommended plasma concentrations of cycloserine were frequent among 
the drug-resistant tuberculosis patients. However, the majority of the patients achieved 
cure defined as five consecutive negative sputum cultures taken every 30 days during 
the last 12 months of treatment (Hung et al., 2014). This study had some limitations to 
consider; low doses of cycloserine were administered and not the recommended 
(Hung et al., 2014). The important investigations with respect to the impact of low 
cycloserine plasma concentrations were not performed and blood was sampled at two 
time points (Hung et al., 2014). 
In anti-tuberculosis drugs, pharmacokinetics plays a major role in either prevention or 
contributing factor to development of drug-resistant tuberculosis. Achieving 
therapeutic plasma drug levels is cardinal for clinical efficacy of anti-tuberculosis 
treatment. Strong evidence from a meta-analysis of controlled clinical trials confirms 
that variability in the pharmacokinetics of a single drug in the anti-tuberculosis drug 
regimen is significantly associated with acquired drug resistance and treatment failure 
(Pasipanodya, Srivastava & Gumbo, 2012). This evidence supports more use of 
individualised dosing than standardised dosing recommended in directly observed 
therapy programmes (Pasipanodya, Srivastava & Gumbo, 2012).  
2.7 POPULATION PHARMACOKINETICS AND MODELLING 
Population pharmacokinetics is defined as the study of sources and correlates of 
variability in drug concentrations between individuals (patients) when standard dosage 
regimens are administered. The essence of population pharmacokinetics is to 
recognise any demographical features (age, weight, and race), pathophysiological 
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(renal and hepatic impairment), concomitant therapies or disease state that can 
significantly alter the pharmacokinetic parameters (Aarons, 1991). It seeks to identify 
the pathophysiological factors that cause changes in the dose-concentration 
relationship that can potentially result in altered therapeutic response. The population 
pharmacokinetics make provision for appropriate dose adjustment or modification 
(Sun et al., 1999). 
The concept of population pharmacokinetics was first proposed by Sheiner and co-
workers in 1977 and has now become a standard tool in the clinical setting and 
pharmaceutical industry (Sheiner, Rosenberg & Marathe, 1977). In population 
pharmacokinetic modelling, a non-linear mixed-effects modelling approach is 
employed. This approach considers the population rather than the individual as the 
unit of analysis for estimating the pharmacokinetic parameters distribution and 
covariate relationship within the population of interest. All pharmacokinetic parameters 
and precision of these parameters are estimated simultaneously (Kiang et al., 2012). 
Population pharmacokinetic modelling is robust and has several advantages, which 
include: 
 Ability to accommodate flexible study designs which occur during treatment, 
 Allow analysis of sparse or dense data from each patient, 
 Ability to screen and quantification of covariates for explaining variability in the 
pharmacokinetic parameters, 
 Ability to distinguish between inter-individual and intra-individual variability in 
the pharmacokinetic parameters, 
 Allow estimation of the magnitude of the unexplained part of the variability in 
the patient population (Charles, 2014, Ette, Williams, 2004). 
 Utilisation of information generated for individualised dosing. 
 Overcome ethical barriers that does not allow performing of traditional Phase 1 
studies in children (Bonate, 2011). 
2.7.1   Role of pharmacokinetic modelling and simulation in anti-tuberculosis 
drugs 
Pharmacokinetic modelling characterises and summarises concentration-time data 
while simulation is applied modelling. Simulation uses models to predict outcomes for 
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a given set of inputs. Monte Carlo simulations unlike deterministic simulations take 
into consideration random variation component of the model to make predictions 
(Bonate, 2011).  
The Monte Carlo simulations were performed on final population pharmacokinetics 
models for second-line anti-tuberculosis drugs in patients with drug-resistant 
tuberculosis with an aim to evaluate World Health Organization and American 
Thoracic Society recommended dosages. The observed data in comparison with 
simulated data revealed none or small proportion of patients achieving target 
concentration range. Hence, authors recommended the following doses: 500 to 750 
mg of cycloserine, 200 mg six hourly of moxifloxacin for patients weighing less than 
50 kg, 750 to 1000 mg IM of kanamycin and 3.3 to 6.6 g twelve hourly or 3.3 g eight 
hourly of para-aminosalicylic acid (Chang et al., 2017). Meanwhile, simulations of the 
600 mg standard dose of rifampicin in another study showed inability to prevent 
emergence of resistance, as probability of target attainment especially in pulmonary 
epithelial lining fluid was less than 36% (Goutelle et al., 2009). However, using 1200 
mg dose produced better results in terms of target attainment (Goutelle et al., 2009). 
The mean bactericidal effect after simulations of 300 mg daily dose of isoniazid was 
11% lower for fast than slow acetylator subjects with MIC of 1 mg/L (Lalande et al., 
2015). Increment of daily dose to 450 mg resulted in a 22% increase in bactericidal 
effect for fast acetylator subjects. These results implied that fast acetylator patients 
infected with low-level resistance mycobacterium tuberculosis might benefit from 
higher doses of isoniazid (Lalande et al., 2015). 
The final pharmacokinetic models in one study (Zvada et al., 2014) were used to 
perform steady-state Monte Carlo simulations of the measures of exposure (AUC and 
Cmax) for tuberculosis-infected patients using World Health Organization 
recommended guidelines (World Health Organization, 2010a). The simulated results 
predicted decreased AUCs by 50% and 56% for isoniazid and rifampicin, respectively. 
Children in the lowest weight band (5.0-7.9 kg) had lower exposures than those in the 
reference adult population (Zvada et al., 2014). These simulation results showed that 
children within the lowest weight band were under-dosed. Furthermore, a dose of 
50mg/kg pyrazinamide was found optimal for children weighing between 5.0 to 7.9 kg, 
as it would achieve the same AUC as in adults. Authors observed wide variability in 
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drug exposure when dosed according to World Health Organization programmatic 
weight bands (Zvada et al., 2014).   
From the studies discussed above, it can be concluded that pharmacokinetic 
modelling and simulation play a role in the determination of effective dose or dosing 
interval for the target patient population. It can further be utilised as a tool for optimal 
individualised anti-tuberculosis drug dose determination and subsequent adjustments. 
2.7.2  The need for terizidone dose optimisation 
There is scanty information available in English language on the use of terizidone in 
tuberculosis besides no studies currently in the scientific literature have attempted to 
optimise terizidone dose in drug-resistant tuberculosis patients. Terizidone in a dose 
of 600-900 mg per day demonstrated a good level of tolerance in five dialysed 
tuberculosis patients (Galietti et al., 1991). Similarly, in the two studies of pulmonary 
tuberculosis patients with concomitant psycho-neurological impairments, tolerated 
well a dose of 250 mg three times daily (Shmelev, Shabalova & Kolosovskaia, 1975, 
(Kottász, Babics, 1972). While terizidone in the above studies was reported to be well 
tolerated at these doses, no plasma concentrations were measured to establish the 
corresponding tolerated plasma concentration range. 
According to South African policy guidelines on the management of drug-resistance 
tuberculosis, patients weighing 33-70 kg take terizidone daily dose of 750 mg in both 
intensive and continuous phase (NDoH, 2013). In addition, the guideline does not state 
the target plasma concentration. Considering the patient weight-band of 33-70 kg and 
the daily dose of 750 mg, it is reasonably justified to speculate that patients within this 
weight-band do not achieve similar plasma concentrations of terizidone. Heavier 
patients are more likely to be under-dosed compared to the lighter ones. 
The plasma concentration profile of terizidone at steady-state in drug-resistant 
tuberculosis patients has not been established. Hence, not only is there a need to 
optimise the dose but also establish effective terizidone exposure (Cmax or AUC) in 
order to prevent resistance and improve treatment outcomes. 
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2.8 SUMMARY 
There is only one study published in English language on pharmacokinetics of 
terizidone in drug sensitive tuberculosis. The pharmacokinetic parameters were not 
accurately estimated due to the use of a non-specific bioanalytical assay (outdated) 
and inappropriate pharmacokinetic model. Cycloserine is the secondary metabolite of 
terizidone. Nevertheless, no pharmacokinetic studies have established the 
pharmacokinetic relationship between terizidone and cycloserine as a secondary 
metabolite. The influence of HIV infection, anti-retroviral therapy and other anti-
tuberculosis drug in the regimen on pharmacokinetics of terizidone in drug-resistant 
tuberculosis patients is not known.  The drug-resistant tuberculosis develops as a 
result of low plasma drug exposure caused by several factors that account for 
pharmacokinetic variability of some drugs in the regimen. Terizidone daily dose of 750 
mg for patients weighing 33-70 kg may not provide sufficient plasma concentrations 
especially in patients with higher body weight.  Good treatment outcomes indicated by 
2 or 3 months sputum culture conversion and other biomarkers are primarily driven by 
adequate plasma concentration of each drug in the regimen. Population 
pharmacokinetic modelling is the best method that can be used to establish 
pharmacokinetic parameter profile of terizidone and cycloserine as its metabolite at 
steady-state.
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Chapter Three 
 
3.0 INTRODUCTION 
The overarching aim of this chapter is to describe the methods and various tools 
employed in order to perform the study objectives outlined in Chapter one. Briefly, the 
chapter describes the study design, site and states the ethical considerations of the 
study. Additionally, the criteria that were applied to either include or exclude the 
patients in the study are outlined. The procedure on how the blood samples from 
patients were obtained and processed has been highlighted. The analytical methods 
to determine the plasma concentrations of terizidone and cycloserine are briefly 
outlined as they have been described in Chapters four and five in detail, respectively. 
The information about the patients’ demographic and clinical characteristics collected 
is provided. The various steps in process of pharmacokinetic modelling of terizidone 
and cycloserine concentration-time data, including the selection of the base, error and 
covariate models have been described. Finally, the chapter concludes by explaining 
the procedure on how the final pharmacokinetic model was validated and used in the 
simulation of current terizidone dose across three weight-bands. 
3.1 STUDY DESIGN AND SITE 
This prospective, non-randomised (non-intervention) clinical study was conducted at 
Brewelskloof Hospital in Worcester, Western Cape province of South Africa. 
Brewelskloof Hospital is one of the designated drug-resistant tuberculosis specialised 
centre in the province. It is a referral hospital to both public and private health 
institutions within the catchment area. The areas catered for by the hospital include 
Caledon, Grabouw, Touws River, De Doorns, Robertson, Montagu, Stellenbosch, 
Swellendam, Bredasdorp, Riviersonderend, Ceres, Kleinmond, Hermanus, Heidberg, 
Paarl, Matjiefontein and Klein Bay.  
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3.1.1 Ethics statement 
The study protocol was approved by the University of the Western Cape ethics 
committee (Reference number: 07/6/12) and University of Cape Town ethics 
committee (Reference number: 777/2014). The study was conducted according to the 
principles stated in the declaration of Helsinki (General Assembly of the World Medical 
Association, 2014) and the guidelines of the National Department of Health of South 
Africa (Department of Health, 2006). The patients were identified by codes. Data 
collected was handled with strict confidentiality. Each patient signed informed consent 
form. Participation in the study was voluntary. Patients had the right to withdraw their 
participation at any stage of the study without consequences. 
3.1.2 Study sample size 
Thirty-nine (39) adult patients with drug-resistant tuberculosis participated in this 
study. Twenty-seven (27) of them were co-infected with human immunodeficiency 
virus (HIV). It was not possible to calculate the minimum number of patients and blood 
samples per patient for pharmacokinetic modelling, as there is no information in 
literature about the population pharmacokinetic model of terizidone.   
3.2 PHARMACOKINETIC SAMPLING DESIGN: COLLECTION OF BLOOD 
SAMPLES 
The full population pharmacokinetics sampling design was applied in order to get 
several 
drug concentrations per patient at different times and to allow for precise estimation 
of pharmacokinetics parameters from the concentration-time data (USFDA, 1999). 
The blood sampling in patients co-infected with HIV was performed as per protocol of 
the main approved study. Blood samples from each patient were collected in 
heparinised tubes at 0h (baseline), 1(±0.5)h, 2(±0.5)h, 3(±0.5)h, 4(±0.5)h, 5h, 8h, 16h, 
and 24h after witnessing intake of terizidone and other second-line anti-tuberculosis 
drugs, including antiretroviral drugs for HIV-infected patients. The blood samples 
underwent centrifugation at 10000 rpm for 5 minutes in order to obtain plasma. 
Harvested plasma was appropriately labeled and stored in a central repository at -
80ºC until drug analysis. 
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3.2.1 Determination of terizidone and cycloserine concentrations in plasma 
The method to analyse terizidone in human plasma was developed and validated 
using high performance liquid chromatography coupled with ultra-violet detection 
(HPLC-UV). 
The method was validated using United States Food and Drugs Administration 
guidelines for analytical method validation and International Conference on 
Harmonisation for validation of analytical procedures (USFDA, 2013, ICH, 2005). The 
detailed procedure of the method is presented in Chapter four. The ultra-performance 
liquid chromatography tandem mass spectrometry method was developed and 
validated for determination of cycloserine in human plasma. The method was validated 
according to the international guidelines (ICH, 2005, USFDA, 2013) and details are 
presented in Chapter five. 
3.3 COLLECTION OF CLINICAL DATA 
3.3.1 Demographic data 
Demographic data such as age, body weight, height and gender were obtained from 
each patient on the day of blood sampling. Body mass index (BMI) was calculated 
using height and body weight (Rolland-Cachera et al., 1991). Free fat mass was 
calculated for each gender using BMI and body weight (Janmahasatian et al., 2005). 
3.3.2 Medical and treatment history 
Medical history regarding HIV status and comorbidities was obtained from the patients’ 
medical records. The dose of terizidone and the current anti-tuberculosis drug regimen 
were documented at the time of pharmacokinetic blood sampling. The antiretroviral 
treatment regimen, current anti-tuberculosis regimen and concurrent medications 
were recorded from the patients’ medical records. 
3.3.3 Liver function tests  
An extra 5 mL of blood was collected from each patient for the determination of alanine 
aminotransferase (ALT), gamma-glutamyl transferase (GGT) and aspartate 
aminotransferase (AST). Other liver function markers such as albumin, unconjugated 
bilirubin, conjugated bilirubin and total bilirubin were analysed as well. 
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3.3.4 Kidney function tests 
Creatinine clearance (Cockcroft, Gault, 1976) and estimated glomerular filtration rate 
(Levey et al., 2007) were calculated using serum creatinine concentration from each 
patient. 
3.3.5 Inclusion criteria 
The inclusion criteria in this study were the following: 
1. Male and female with confirmed drug-resistant tuberculosis with or without HIV 
infection, 
2. Age ranging from 17 to 65 years,  
3. Intensive phase treatment of drug-resistant tuberculosis for at least two weeks, 
4. Being treated with second-line anti-tuberculosis drugs (kanamycin or amikacin, 
moxifloxacin, ethionamide, terizidone, ethambutol, isoniazid and 
pyrazinamide), 
5. Informed signed consent form.  
3.3.6 Exclusion criteria 
If the patients had the following characteristics, they were excluded from the study: 
1. Paediatric patients, 
2. Pregnant patients,  
3. Patients with unstable haemodynamics, 
4. Extensively drug-resistant tuberculosis, 
5. Absence of informed signed consent form. 
3.4 DETERMINATION OF PHARMACOKINETIC PARAMETERS 
The population pharmacokinetics analysis approach was employed (Sun et al., 1999). 
The population pharmacokinetic model consists of three sub models namely; (1) 
structural model (which describes the overall pattern of data using fixed effects 
parameters), (2) statistical or stochastic model (which accounts for variability by using 
a hierarchy of random effects  e.g. inter-individual variability, inter-occasion variability 
and residual variability) and (3) covariate model (which expresses relationships 
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between model parameters and covariates). The population pharmacokinetic model is 
the set of models for individual observation and generally represented as equation (1): 
𝒚𝒊𝒋 = 𝒇𝒊𝒋 (𝜱𝒋, 𝒙𝒊𝒋) + 𝜺𝒊𝒋                (𝟏) 
Where 𝒚𝒊𝒋 is the vector of observed data like drug plasma concentrations at respective 
time points 𝒙𝒊𝒋 of the j
th subject.  𝒇𝒊𝒋 is the function for the prediction of the i
th response 
in the jth subject.  𝜱𝒋 represents the vector of estimable pharmacokinetic parameters 
of the jth subject and  finally 𝜺𝒊𝒋 is the i
th measurement error in the jth subject. 
Furthermore 𝜱𝒋 is represented as equation (2):  
𝜱𝒋 = 𝒈 (𝜽, 𝒛𝒋) + 𝜼𝒋                        (𝟐) 
Where g is a function describing the expected value of 𝜱𝒋 as a function of known 
individual specific covariates 𝒛𝒋  and the vector of population parameters 𝜽. 𝜼𝒋 
represents the random variation of individual parameters around the (mean) 
population prediction (Ette, Williams, 2004).  
The concentration-time data for terizidone and cycloserine was analysed by employing 
the non-linear mixed-effects (NLME) modelling implemented in Monolix 2018R1 
software  (Lixoft, 2018). The software implements a stochastic approximation of the 
standard expectation maximization (SAEM) algorithm (Kuhn, Lavielle, 2005) for NLME 
models without approximations. The primary pharmacokinetic parameters such as 
absorption rate constant (ka), apparent volume of distribution (V/F) and apparent 
clearance (Cl/F) were estimated.  
The secondary pharmacokinetic parameters such as area under the curve (AUC0-24) 
and half-life were estimated using the final validated model without covariates. The 
Monolix MlxTran model file used to execute the estimation of secondary 
pharmacokinetic parameters is included in this thesis as Appendix 1. The values for 
the maximum concentration (Cmax) and the time at which concentration is at Cmax (Tmax) 
were obtained from the file output of the individual predicted concentrations. 
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3.5  PHARMACOKINETIC MODEL BUILDING STRATEGY 
3.5.1 Selection of the base and error model 
The data set was explored using DatXplore interface in Monolix and relationships 
among the covariates were established. Selection of the pharmacokinetic structural or 
base model was aided by graphical exploration of concentration-time data for 
terizidone and cycloserine using ggplot2 package in R statistical software (R Core 
Team, 2018) in addition to DatXplore. The overall pattern of the time versus log-
transformed concentration of terizidone and cycloserine profile determined the 
pharmacokinetic structural model to be initially selected. The concentration-time data 
for terizidone and cycloserine were modelled simultaneously using Monolix.  One-
compartment model was selected initially with constant or additive error model (𝒚 =
𝒇 + 𝒂 𝜺) without inclusion of covariates. Several error models such as proportional 
(𝒚 = 𝒇 + 𝒃 𝒇 𝜺), combined1 ( 𝒚 = 𝒇 + (𝒂 + 𝒃 𝒇) 𝜺), combined2, (𝒚 = 𝒇 +  √(𝒂𝟐 +
𝒃𝟐 𝒇𝟐 𝛆)), and exponential (𝐥𝐨𝐠(𝒚) = 𝐥𝐨𝐠(𝒇) + 𝒂 𝜺) were tried as well iteratively in order 
to get the best error model. The error model associated with the lowest Objective 
Function Value (OFV) or Bayesian Information Criterion–BIC was selected (Schwarz, 
1978). The two-compartment model was tried with several error models as for the one-
compartment model.  
After performing several runs, the selection of the best base model (structural) was 
based on visual inspection of individual fit plots as well as observed versus individual 
predicted concentration (IPRED) plots.  
Selection of best error model was based on goodness-of-fit plots that included 
individual weighted residuals (IWRES) versus time plot and a plot of absolute values 
of IWRES (|IWRES|) versus IPRED. A lack of visible trend in both plots was the criteria 
for the appropriate error model. Additionally, the inspection of parameter distribution 
(Empirical Bayes Estimates–EBEs) plots of the simulated rather than the empirical 
distribution of the estimated individual parameters (Lavielle, Ribba, 2016) was 
performed. At every modelling stage, the structural and error models were assessed 
for any mis-specification. 
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3.5.2 Random effects  
The distribution of standardised random effects associated with each estimated 
pharmacokinetic parameter (fixed effects) were assessed for normality by visual 
inspection of boxplots generated in Monolix. The model for random effects was thus 
accepted if the boxplots were in agreement or did not deviate from the expected 
standard normal distribution. 
3.5.3 Covariate modelling 
The covariate modelling was performed in a stepwise manner (Mandema, Verotta & 
Sheiner, 1992) and iteratively. The basic population pharmacokinetic model without 
any covariates, developed from the above described procedure was the starting point 
in the covariate modelling. Allometric scaling of all disposition parameters was applied 
in order to adjust for the expected effect of body size (Anderson, Holford, 2009) using 
body size descriptors like free fat mass (Janmahasatian et al., 2005), total body weight 
and body mass index. The correlations among the covariates were analysed in order 
to identify the possibility of collinearity. Pharmacological or biological plausible 
covariates were selected for covariate model building. In the case of collinearity, only 
one of the correlated covariates was included in the model. 
3.5.4 Screening for covariate effects 
Selection of covariate significance (pharmacologically or biologically plausible) was 
achieved through graphical observation of correlation trends between random effects 
of individual predicted pharmacokinetic parameters and continuous covariates in 
Monolix interface. In the case of categorical covariates, the boxplots of random effects 
of individual predicted pharmacokinetic parameters were assessed for any visible 
differences in the medians as the criteria for inclusion in the covariate model. 
Therefore, any visible trend between random effects and individual predicted 
parameters indicated eligibility of a covariate for inclusion in the covariate model. 
Covariate modelling included the determination of relationship between various 
covariates (patient demographic variables, HIV status, liver and renal function markers 
and co-morbidities) and fixed parameters using Wald test integrated in Monolix. All 
continuous covariates were centered around the median value (typical median value). 
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The covariates that met the inclusion criteria as stated above were tested one at a 
time in a stepwise forward inclusion manner. A p-value of ≤ 0.05 (Wald test) was 
considered significant provided the OFV (−2 ∗ 𝑙𝑜𝑔𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑) decreased by at least 
3.84 points (goodness-of-fit criteria). After inclusion of all the significant covariates (full 
model), a backward deletion step was performed at the significance level of ≤ 0.01 
provided there was a decrease in OFV by at least 6.63 points. The final population 
pharmacokinetic model (reduced model) consisted of relevant covariates of interest 
that were evaluated and retained. 
3.5.5 Model diagnosis 
The final population pharmacokinetic model was subjected to four types of model 
diagnoses in order to evaluate its validity. These were individual parameter estimates 
based diagnosis, residual type diagnosis, simulation based diagnosis and numerical 
diagnosis (Karlsson, Savic, 2007).  
The individual parameter estimates based diagnosis involved the plot of the 
distribution of individual predicted parameters and the shrinkage. The low value of 
shrinkage and approximate normal distribution observed through histograms and QQ-
plots of the EBEs was desirable. The other diagnostic test performed was plot of 
observed concentrations versus predicted concentrations (IPRED) in order to test if 
there was agreement.   
Residual type diagnosis involved the plot of IWRES and time in order to identify any 
trend in the IWRES over time (independent variable). Model misspecification was 
assumed if there was a clear trend in the IWRES. 
Simulation based model diagnosis involved the visual predictive checks (VPC) (Wang, 
Zhang, 2012). The VPC evaluated the predictability of final pharmacokinetic model by 
making graphical comparison between the multiple model-simulated predictions at 
each time point from the data set and observed data. The simulation of the single data 
set was also performed and compared with the observed data set (Karlsson et al., 
1998). 
Numerical diagnostics involved comparison of the OFV (−𝟐 ∗ 𝒍𝒐𝒈𝒍𝒊𝒌𝒆𝒍𝒊𝒉𝒐𝒐𝒅) 
between nested models or comparison of BIC between non-nested models. The 
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smaller the OFV or BIC value the better was the model. Model over fit was also 
assessed by the magnitude of relative standard errors of the pharmacokinetic 
parameters (Karlsson, Savic, 2007). High values indicated possible over fit. Finally, a 
bootstrap procedure was performed in Monolix aided by Rsmlx R package (Lavielle, 
Chauvin & Tran, 2018) in order to assess the precision of the parameters and 
robustness of the proposed joint population pharmacokinetic model. 
3.6 Monte Carlo simulation 
The final joint population pharmacokinetic model was used to simulate terizidone and 
cycloserine exposure (AUC0-24 and Cmax) at 750 mg terizidone daily dose across the 
three weight bands, 33 – 50, 51 – 70 and > 70 kg. This was done in order to assess 
whether similar exposure was achieved across these weight bands. In patients 
weighing 51 – 70 and > 70 kg, dosage optimisations were performed to achieve 
exposures similar to those in 33 – 50 kg weight band and taking 750 mg of terizidone 
daily. 
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Chapter Four 
 
In this chapter, a research paper entitled: 
“Analysis of Terizidone in Plasma using HPLC‐UV method and its Application 
in a Pharmacokinetic Study of Patients with Drug-resistant Tuberculosis”, 
is presented. It was published as a research article in the Biomedical Chromatography, 
2018, 32(11): e4325. https://doi.org/10.1002/bmc.4325. It has been re-used in this 
thesis with permission from the publisher (John Wiley & Sons, Inc. license number 
4476471000780). The Copyright license agreement is included as Appendix 2. 
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https://doi.org/10.1002/bmc.4325Abstract
A chromatographic method has been developed and validated for the first time for
analysis of terizidone in plasma. Terizidone was extracted from plasma by protein pre-
cipitation using a mixture of acetonitrile and methanol (1:1, v/v). The chromatographic
separation was achieved with a gradient of acetonitrile and water both containing
0.1% formic acid on a Supelco Discovery® HS C18 (150 ×4.6mm, 5μm) reversed‐
phase column. Propranolol was used as the internal standard. The total run‐time
was 18min. The calibration standard concentrations ranged between 3.125 and
200μg/mL and calibration curves were linear with coefficient of determination values
in the range of 0.9988–0.9999. The inter‐ and intra‐day assay precision (percentage
relative standard error) was <15% while mean accuracy was 107%. The mean extrac-
tion efficiencies of terizidone and IS were 76 and 89%, respectively. The validation
results demonstrated that the method was selective and sensitive, and that terizidone
was stable under the studied conditions. The method was successfully applied in a
population pharmacokinetic study. The mean plasma concentration of terizidone in
patients at all sampling time points was 51.8 ± 28μg/mL. The method was simple,
cheap and hence suitable for therapeutic drug monitoring of terizidone.
KEYWORDS
HPLC‐UV, multidrug‐resistant tuberculosis, plasma, Terizidone1 | INTRODUCTION
Tuberculosis remains a major world health problem and ranks as the
ninth leading cause of death in the world (WHO, 2017). If not properly
managed, drug‐resistant tuberculosis (DR‐TB) emerges as a complica-
tion of tuberculosis (Zumla et al., 2012). Consequently, DR‐TB neces-
sitates the use of a second‐line anti‐tuberculosis drugs regimen, which
usually contains five to seven drugs (WHO, 2014).
Terizidone is one of the second‐line drugs used in both intensive
and continuous phases of DR‐TB treatment in South Africa (NDoH,
2013). It is made up of two molecules of cycloserine that are joined
by a molecule of terephtalaldehyde and reported to have fewer
adverse effects than cycloserine (Bartmann et al., 2013; Kottász &
Babics, 1972; Vora, 2010). For DR‐TB treatment to be successful,wileyonlinelibrary.co56http://etd.uwthe plasma concentration of each drug in the regimen must reach
the effective threshold necessary to kill the bacteria. In fact, studies
have confirmed that variability in the plasma exposure of anti‐tubercu-
losis drugs is one of the main causes of emergence of DR‐TB or poor
treatment outcomes (Chideya et al., 2009; Pasipanodya, Srivastava, &
Gumbo, 2012; Srivastava, Pasipanodya, Meek, Leff, & Gumbo, 2011).
Adequate plasma drug exposure and an optimal regimen not only pre-
vent the emergence of DR‐TB but also promote early desired treat-
ment outcomes (Pasipanodya et al., 2013; Yuen et al., 2015).
Therefore, therapeutic drug monitoring, which involves the measuring
of plasma concentration of drugs at specific times after drug adminis-
tration, is of utmost importance (Alsultan & Peloquin, 2014). Further-
more, the knowledge of the pharmacokinetic properties of drugs
used in DR‐TB aid in determining appropriate doses should drug© 2018 John Wiley & Sons, Ltd.m/journal/bmc 1 of 7
c.ac.za/
2 of 7 MULUBWA AND MUGABOplasma concentrations be found to be lower or higher than the
expected threshold (Reynolds & Heysell, 2014).
Terizidone has scarce information about its pharmacokinetics in
the literature (WHO, 2015). In one pharmacokinetic study (Zitkova &
Toušek, 1974), terizidone plasma concentration was determined using
the calorimetric method (Jones, 1956), which is neither specific nor
currently used in determination of plasma drug concentrations. How-
ever, literature from the World Health Organization (WHO, 2015)
states that terizidone is not measurable in plasma and thus is thought
to undergo complete pre‐systemic hydrolysis in the gut wall and liver.
The objective of the current study was to develop and validate
the first chromatographic method to determine terizidone concentra-
tions in plasma and verify its presence in patient plasma samples for
a population pharmacokinetic study.2 | EXPERIMENTAL
2.1 | Chemicals and reagents
Terizidone powder, analytical grade (catalog no. T115500, Figure 1),
was obtained from Toronto Research Chemicals, Canada. Propranolol
powder (lot no. 29H4016), used as the internal standard (IS), was pur-
chased from Sigma‐Aldrich, Germany. HPLC‐grade acetonitrile and
methanol were sourced from Sigma‐Aldrich and Merck (South Africa),
respectively. Dimethylsulfoxide (DMSO) and formic acid were sourced
from Merck, South Africa. Ten other drugs (ethionamide, ethambutol,
kanamycin, isoniazid, moxifloxacin, stavudine, lamivudine, tenofovir,
pyrazinamide and efavirenz) that are usually co‐administered with
terizidone were obtained from Western Cape Provincial Pharmaceuti-
cal Services (South Africa). Cycloserine powder (CAS no. 68‐41‐7) was
purchased from Sigma‐Aldrich, Germany. The HPLC‐grade water (18
mΩ) was obtained from a Direct‐Q3 (Mmillipore) water purification
system. Drug‐free pooled plasma was purchased from Sigma‐Aldrich.TABLE 1 Gradient elution steps2.2 | Instrumentation
The analysis of terizidone was performed on a Waters® 1525 HPLC
system (Milford, MA, USA) equipped with binary pumps with maxi-
mum operating pressure of 6000 psi and a programmable range of
flow‐rate between 0.00 to 10.00mL/min in 0.01mL increments. The
system comprised an integral vacuum degasser for removal of dis-
solved gases from the mobile phase. Linked to the system was a
Waters® 717 plus autosampler and Waters® 2487 (dual absorbance)
UV detector, which was set at a sensitivity of 2.0000 AUFS. The han-
dling of data was managed by Empower pro software.FIGURE 1 Chemical structure of terizidone
57http://etd.uw2.3 | Chromatographic and analytical conditions
The chromatographic separation of terizidone and IS was achieved
using a reversed‐phase Supelco Discovery® HS C18 column
(150 × 4.6mm, 5 μm). The mobile phase used was water containing
0.1% formic acid (A) and acetonitrile containing 0.1% formic acid (B).
Gradient elution was carried out using the steps shown in Table 1.
Terizidone and IS were both monitored with the Waters® 2487 UV
detector set at 260 nM. The sample injection volume was 20 μL. The
HPLC analysis was performed at a flow rate and temperature,
1.2mL/min and 20°C, respectively.2.4 | Preparation of stock solutions, calibration
standards and quality controls
Stock solution of terizidone at 2mg/mL (2000 μg/mL) was prepared
by dissolving accurately weighed 20.0mg of terizidone powder in
2mL of DMSO and made up to 10mL mark with methanol in a
10mL volumetric flask. Stock quality control (QC) solution of
terizidone was prepared at concentration 1.5mg/mL (1500 μg/mL)
by dissolving 15.0mg of terizidone powder in 2mL of DMSO and
made up to 10mL with methanol in a 10mL volumetric flask. The IS
stock solution was made at 0.4mg/mL (400 μg/mL) by dissolving
20.0mg of propranolol in methanol using a 50mL volumetric flask.
These solutions were kept at −20°C.
Seven standards for the calibration curve were prepared in the
range 3.125–200 μg/mL by spiking 0.3mL of terizidone stock solution
in 2.7mL of drug‐free plasma and diluting serially with drug‐free
plasma. Drug‐free plasma (1.8mL) was spiked with 0.2mL of
terizidone QC stock solution and appropriately diluted with drug‐free
plasma. The QC samples, low (LQC), medium (MQC) and high (HQC),
were thus prepared at 10, 37.5 and 150 μg/mL, respectively.2.5 | Plasma sample treatment
The IS stock solution (in methanol) was diluted with equal volume of
acetonitrile to 200 μg/mL. To every 200 μL of spiked plasma (calibra-
tion standards and QC samples), 800 μL of IS solution (200 μg/mL)
was added and vortex mixed for 1min. The protein precipitate was
then separated through centrifugation (10,000 rpm) at 2°C for
10min. The supernatant (800 μL) was pipetted into a clean vial and
20 μL was injected onto HPLC system.Time Flow rate (mL/min) A (%) B (%)
0.0 1.2 90.0 10.0
1.0 1.2 90.0 10.0
10.0 1.2 0.0 100.0
13.0 1.2 0.0 100.0
13.1 1.2 90.0 10.0
18.0 1.2 90.0 10.0
c.ac.za/
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The validation of the method was performed according to the interna-
tional guidelines (ICH, 2005; USFDA, 2013) for quantification of the
limit of detection (LOD), lower limit of quantification (LLOQ) or sensi-
tivity, selectivity, linearity, accuracy, precision, carry‐over, recovery
and stability.2.7 | Analysis of patients’ plasma samples
Patients’ plasma samples kept at −80°C were left to thaw at room tem-
perature. To each 200 μL of patient plasma, 800 μL of IS was added.
The rest of the sample preparation process was the same as for the cal-
ibration standards. The analytical run consisted of blank sample (proc-
essed plasma without IS and terizidone), zero blank (processed plasma
with IS only), calibration standards, patient samples and QC samples.FIGURE 2 Chromatograms of IS (a), LLOQ
(b) and highest calibration standard (c)
58http://etd.uw3 | RESULTS AND DISCUSSION
3.1 | Optimization of chromatographic conditions
The use of a mixture of methanol and acetonitrile (1:1, v/v) as precip-
itating solvent improved the extraction of the analyte and IS from the
plasma. Other ISs tested apart from propranolol were acyclovir and
reserpine. The separation of the analyte and IS was tried on three dif-
ferent columns, namely a Kinetex XB C18 (150 × 2.1mm, 2.6 μm), a
Zorbax Eclipse XDB C8 (150 × 4.6mm, 5 μm) and a Luna C8
(250 × 4.6mm, 5 μm). The organic mobile phases tested were methanol
and acetonitrile. A buffer solution of octane sodium sulfonic acid and
sodium bicarbonate at pH of 8 and 9 was tried too. The optimization
objective was to achieve well‐separated sharp peaks of both analyte
and IS as well as a short run‐time. Isocratic separation was tried first
followed by gradient elution. In all of the chromatographic trial runs,c.ac.za/
TABLE 2 Retention time for analyte, IS and other drugs
Drugs Retention time (min)
Cycloserine 0.21*
Ethionamide 4.80
Ethambutol 1.43
Efavirenz 3.62
Isoniazid 1.55
Lamivudine 3.23
Kanamycin 1.90
Moxifloxacin 6.94
Tenofovir 8.06
Stavudine 5.87
Pyrazinamide 4.18
Propranolol (IS) 10.53 ± 0.024
Terizidone (analyte) 11.62 ± 0.029
*Cycloserine peak was in the void and very small.
TABLE 3 Parameters describing the linearity of the calibration curve
Run number r2 Equation Residual sum of squares
1 0.9999 y = 0.0103x − 0.026 0.00029
2 0.9998 y = 0.011x − 0.0115 0.00058
3 0.9999 y = 0.0112x − 0.0074 0.00019
4 0.9996 y = 0.0107x − 0.0223 0.00121
5 0.9999 y = 0.0102x − 0.0192 0.00034
6 0.9988 y = 0.0104x − 0.0032 0.00353
4 of 7 MULUBWA AND MUGABOisocratic elution was found to be unsuitable. Hence, more time was
spent in determining the best gradient steps at different flow rates.
Terizidone's chemical structure comprises two cycloserine
structures joined by terephthalaldehyde moiety (Figure 1). The
terephthalaldehyde moiety renders terizidone less polar than cycloser-
ine. Hence, terizidone was retained more on a high‐surface‐area (HS
C18) column than cycloserine. Increasing the water content (polar
mobile phase) in the first step of the gradient insured the repulsion
of tezidone from the mobile phase and onto the nonpolar stationary
phase (HS C18), leading to a longer retention time, while increasing
the organic mobile phase (acetonitrile) in the second step of the gradi-
ent speeded up the elution of terizidone. Acetonitrile was preferred to
methanol because it has a higher elution strength than methanol on
C18 columns.
The mobile phase consisting of acetonitrile and water with 0.1%
formic acid generally produced good peaks of both IS and analyte.
Addition of formic acid to acetonitrile (0.1%) produced sharper peaks
than acetonitrile without formic acid. Therefore, the mobile phases
found to be optimal were 0.1% formic acid in acetonitrile and 0.1%
formic acid in water with gradient elution steps and flow rate as
shown in Table 1. The column, an HS C18 column (150 × 4.6mm,
5 μm) best separated the IS and analyte with a run‐time of 18min,
as shown in Figure 2. The LC/MS method was initially tried but
terizidone had problems with ionization. Therefore, it was difficult to
detect its ion.
3.2 | Method validation
3.2.1 | Selectivity
Selectivity of the analytical method was tested by assessing possible
interference by co‐administered drugs and cycloserine (analyte metab-
olite). The drugs—ethionamide, ethambutol, kanamycin, isoniazid,
moxifloxacin, stavudine, lamivudine, tenofovir, pyrazinamide, efavirenz
and cycloserine—were each and in combination tested at 10 μg/mL.
These drugs did not show any interference or co‐elution at the reten-
tion times of the IS (propranolol) and the analyte (terizidone). The
method was therefore able to differentiate the analyte and IS from
co‐administered drugs. The retention time for each drug is shown in
Table 2. The interference from endogenous compounds was not
assessed as pooled plasma was used. However, 5‐fold dilution of
plasma with IS solution (200 μL in 1000 μL) from the sample prepara-
tion procedure also resulted in dilution of the endogenous com-
pounds. Hence, the interference of the endogenous compounds was
assumed to be negligible.
3.2.2 | Sensitivity, LOD and linearity
The LLOQ or sensitivity was the lowest concentration of the calibra-
tion standards that was reliably quantified with accuracy within 20%
of the nominal concentration and precision of ≤20% of the relative
standard deviation (RSD) of the back‐calculated concentration
(USFDA, 2013). Each calibration standard was injected six times. The
concentration of 3.125 μg/mL met the criterion for the LLOQ as it
had an accuracy of 118.9%, which was within 20% of the nominal con-
centration with an RSD of 9.43%. Half of the concentration of the
LLOQ (1.562 μg/mL) could not meet the criteria as it had an accuracy59http://etd.uwof 158% and an RSD of 25.1%, and hence was excluded from the
calibration curve.
The LOD was determined by visual evaluation of the analyte peak
(ICH, 2005). The LLOQ sample was serially diluted with plasma to
three concentrations levels: 1.56, 0.78 and 0.39 μg/mL. The response
(peak) corresponding to the concentration of 0.78 μg/mL was reliably
clear and hence considered as the LOD.
The calibration curve was constructed from the plot of chromato-
gram peak area ratios of the analyte and the IS as a linear function of
the analyte nominal concentration. The average coefficient of deter-
mination (r2) obtained from six replicate analytical runs of the seven
calibration standards was 0.9997. The average of the residual sum of
squares was 0.001. Table 3 shows the summary of linearity parame-
ters. Therefore, the curve was linear over the concentration range
3.125–200 μg/mL.3.2.3 | Precision and accuracy
The accuracy of the analytical method was determined by replicate
analysis of LLOQ, LQC, MQC and HQC. The results are presented in
Table 4. Accuracy was expressed as the percentage ratio of the mean
back‐calculated concentration and nominal concentration. It ranged
between 99.7 and 118.9% for both within‐ and between‐run accuracy
and was within the acceptable limits (USFDA, 2013). Precision,
expressed as percentage relative standard deviation (RSD), was deter-
mined from the replicate analysis of LLOQ, LQC, MQC and HQC
within an analytical run (on one day) and between analytical runs (onc.ac.za/
TABLE 4 Within‐run and between‐run precision and accuracy of the analytical assay for LLOQ, LQC, MQC and HQC
Nominal concentration (μg/mL) Mean concentration, ± SD (μg/mL) RSD (precision, %) Accuracy (%)
Within‐run analysis
3.125a 3.7 ± 0.35 9.4 118.9
10b 11.3 ± 0.33 2.97 112.7
37.5b 38.1 ± 0.19 0.50 101.6
150b 149.6 ± 0.53 0.35 99.7
Between‐run analysis
3.125b 3.4 ± 0.58 17.35 107.2
10b 10.7 ± 0.73 6.79 107.4
37.5b 38.8 ± 0.98 2.52 103.5
150b 150.8 ± 2.23 1.48 100.5
aSix replicates.
bFive replicates.
SD, Standard deviation.
MULUBWA AND MUGABO 5 of 7different days). As shown in Table 4, the within‐run precision ranged
between 0.35 and 9.4% while between‐run precision ranged between
1.48 and 17.35%, which was within acceptable limits (USFDA, 2013).3.2.4 | Carry‐over and recovery
Carry‐over was assessed by injecting a blank sample (without IS and
analyte) after the highest concentration sample (200 μg/mL) of the
calibration standard. There was no noticeable peak at the retention
time for the analyte or IS. Hence, there was no carry‐over observed.
Recovery or extraction efficiency was evaluated by comparing the
instrument response (peak area) of the analyte extracted from theFIGURE 3 Chromatograms of terizidone from a patient at six sampling t
60http://etd.uwplasma and peak area of the analyte prepared in the solvent (USFDA,
2013). The recoveries of the analyte at 3.125 and 200 μg/mL were
66.7–70.% and 79.8–80.2%, respectively. The overall mean extraction
for the analyte was 75.6%. The extraction efficiency of the IS was
80.6–94.3% with a mean of 88.5%.3.2.5 | Stability
The analyte stability assessment was carried out according to the sit-
uations likely to be encountered during patient plasma sample prepa-
ration and analysis (USFDA, 2013). These situations were the
maximum number of freeze–thaw cycles and the maximum time theime points (0–24 h)
c.ac.za/
FIGURE 4 Boxplot of terizidone concentrations in patients with
drug‐resistant tuberculosis
6 of 7 MULUBWA AND MUGABOsamples remained in the autosampler at 20°C for each batch analysis.
After three freeze–thaw cycles, the concentrations of the HQC and
LQC samples dropped by 0.37% (0.74 μg/mL) and 1.9% (0.12 μg/
mL), respectively. However, the concentrations of HQC and LQC
samples after 24 h in the autosampler did not change. Therefore, the
analyte was stable in all circumstances where patient plasma samples
were prepared and analyzed.3.3 | Method application in a pharmacokinetic study
The method developed was used to determine the concentration of
terizidone in patient plasma samples for a population pharmacokinetic
study. The study involved 78 DR‐TB patients who were undergoing an
intensive phase of treatment for at least 2 weeks (steady state). A total
of 608 plasma samples were analyzed but terizidone was only found in
272 samples from 39 patients. There was no chromatographic peak
seen at terizidone retention time for all samples that did not have
terizidone. Figure 3 depicts a typical example of terizidone chromato-
grams from a patient with blood sampled at baseline (0), 3, 3.5, 5, 8
and 24 h. The median and mean concentrations from the 39 patients
were 49.3 (4.3–176.1) and 51.8 ± 28.1 μg/mL, respectively. The sum-
mary distribution of the concentrations is shown in Figure 4. To our
knowledge, this is the first chromatographic method developed to
analyze terizidone in plasma.4 | CONCLUSION
The HPLC‐UV method was hereby developed and validated, and for
the first time, successfully applied to determine plasma concentration
of terizidone in patients with DR‐TB. The method is simple and does
not require expensive instrumentation or reagents. The validation61http://etd.uwresults demonstrate unequivocally that the method is selective, sensi-
tive, linear, accurate, precise and stable. The method is suitable for
therapeutic drug monitoring of terizidone in DR‐TB patients, unlike
monitoring of its metabolite (cycloserine). As the literature on
terizidone dose optimization is scarce, the current method is appropri-
ate for pharmacokinetic studies in order to establish optimal doses.
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ABSTRACT 
A simple and sensitive ultra-performance liquid chromatography tandem mass 
spectrometry method has been developed and validated for the analysis of cycloserine 
in patients’ plasma. Using methanol, cyloserine and propranolol (internal standard–IS) 
was extracted from plasma by protein precipitation procedure. The chromatographic 
separation was successfully achieved on Phenomenex KinetexTM PFP C18 (2.1 mm x 
100 mm, 2.6 µm) reversed-phase column. Acidified with 0.1 % formic acid, water and 
acetonitrile were used as mobile phases for gradient elution. Cycloserine and IS were 
detected by Xevo® TQ MS triple quadrupole tandem mass spectrometer. The transition 
of protonated precursor to product ion were monitored at 103→75 m/z and 260.2→183 
m/z for cycloserine and IS, respectively. The lower limit of quantification was 0.01 
µg/mL. The method was linear over the concentration range 0.01–50 µg/mL with 
average coefficient of determination of 0.9994. The within-run and between-run 
precision and accuracy were in the range 3.7–19.3% (RSD) and 98.7–117.3%, 
respectively. Processed cycloserine sample was stable for 48 hours at 8 ⁰C and after 
three freeze-thaw cycles. The extraction efficiency ranged between 88.7 and 91.2%. 
The method was successfully applied in a pharmacokinetic study for the determination 
of cycloserine in plasma of patients with drug-resistant tuberculosis.  
Keywords: Cycloserine, UPLC-MS/MS, plasma, drug-resistant tuberculosis. 
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5.0 INTRODUCTION 
Cycloserine is a structural analogue of D-alanine, a broad-spectrum antibiotic, 
naturally produced from Streptomyces lavendulae and Streptomyces garyphalus 
(Batson et al., 2017). It is clinically used as the second-line drug for treatment of 
multidrug-resistant tuberculosis (World Health Organization, 2014). Cycloserine exerts 
bacteriostatic (Di Perri and Bonora, 2004) action by preventing the biosynthesis of 
peptidoglycan through inhibition of D-alanine:D-alanine ligase and alanine racemase 
of the Mycobacterium tuberculosis (Prosser and de Carvalho, 2013).  
Cycloserine is water soluble and absorbed faster in healthy individuals than 
tuberculosis patients (Chang et al., 2017, Zhu et al., 2001). It distributes widely in body 
fluids and tissues. Primarily the kidneys excrete it mostly in unchanged form. The 
clearance is lower in healthy individuals than in tuberculosis patients (Brennan et al., 
2008). Although cycloserine is effective in treating resistant strains of Mycobacterium 
tuberculosis, its use is limited due to severe toxicities on the kidney and 
neuropsychiatric adverse reactions (Batson et al., 2017, World Health Organization, 
2014). Consequently, the World Health Organization (World Health Organization, 
2014) recommends monitoring of cycloserine plasma concentration to ensure that the 
peak concentration is kept below 35 µg/mL.  
Determination of plasma concentration of cycloserine or any drug requires a method 
that has less steps in sample preparation and better sensitivity. Several bioanalytical 
methods for cycloserine employing LC-MS/MS have been described in literature 
(Polagani et al., 2013, Patel et al., 2011, Mao et al., 2017, Yaroshenko et al., 2014) 
with sensitivities in the range 0.05 – 0.5 µg/mL. The other HPLC-MS and HPLC-
MS/MS methods had sensitivities of 0.5 and 0.2 µg/mL, respectively (Stepanova et al., 
2016, Supriya et al., 2012). Three of these methods employed solid phase extraction 
procedure, which is expensive and time consuming. The other methods made use of 
protein precipitation and derivatisation (Polagani et al., 2013, Mao et al., 2017, 
Stepanova et al., 2016) that involved several steps and used very small volumes of 
reagents. More errors are likely to be made if small volumes of reagents are used in 
sample processing, which eventually affect precision. 
http://etd.uwc.ac.za/
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The only UPLC-MS/MS method (Han et al., 2013) for cycloserine analysis available 
has two shortcomings. Firstly, many steps are involved when mixing volumes of 
reagents. Moreover, the method required a sample to be centrifuged twice before it is 
ready for analysis. Secondly, as small as 4 and 5 µL volumes of reagents were used 
in sample preparation process. These pitfalls compromise the precision and accuracy 
especially if the method is adapted for routine batch analysis of clinical samples. The 
objective of this study was to develop a bioanalytical method that has less steps in 
sample preparation, simple as well as better sensitivity for analysis of cycloserine in 
plasma of patients.  
Therefore, in the current study a simple, stable and sensitive UPLC-MS/MS method 
was developed and validated for the determination of cycloserine in plasma. The 
method was applied to quantify cycloserine as a metabolite of terizidone in 
pharmacokinetic study of patients with drug-resistant tuberculosis.  
5.1 EXPERIMENTAL 
5.1.1 Chemical reagents 
The reference standard, cycloserine (Figure 1) powder, analytical grade (CAS: 68-41-
7) and propranolol powder (internal standard–IS, Figure 1) analytical grade (Lot: 
29H4016) were purchased from Sigma-Aldrich, Germany. The HPLC grade of 
methanol and acetonitrile were purchased from Merck (South Africa) and Sigma-
Aldrich (Germany), respectively. Formic acid was acquired from Merck, South Africa. 
Water (18 mΩ) was obtained from a Direct-Q3 (Mmillipore) water purification system. 
Blank pooled plasma (for research purpose) was purchased from Sigma-Aldrich, 
Germany. 
http://etd.uwc.ac.za/
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Figure 1. Chemical structure of cycloserine (A) and propranolol (B). 
5.1.2 Instrumentation  
The analytical equipment consisted of a Waters® Acquity (Waters, Milford, MA, USA) 
ultra-performance liquid chromatography (UPLC) system. It consisted of a binary 
solvent manager with two independent pump systems that pumped solvent through 
the system with a maximum pressure of 15000 psi. The Sample manager injected 
samples that were drawn from the vials located in the Sample organiser onto the 
chromatographic column. The system was also equipped with a column heater. 
Temperature in the Sample organiser was kept at 10 ⁰C. Coupled to the UPLC system 
was a Xevo® TQ MS triple quadrupole tandem mass spectrometer (atmospheric 
pressure ionisation) and was used for high-resolution UPLC-MS/MS analysis. The 
MassLynxTM software, acquired, managed and processed the mass spectrometry data 
and UPLC instrument control. 
5.1.3 Chromatographic and mass spectrometry conditions 
Separation of cycloserine and propranolol was carried out on Phenomenex KinetexTM 
PFP C18 (2.1 mm x 100 mm, 2.6 µm) reversed-phase column. The column temperature 
was maintained at 45 ⁰C. The mobile phases consisted of water (A) and acetonitrile 
(B) both acidified with 0.1 % formic acid. The gradient steps in Table 1 were used to 
elute cycloserine and propranolol at flow rate of 0.4 mL/min. The total chromatographic 
run time was 7 minutes.  
 
http://etd.uwc.ac.za/
Chapter Five 
 
68 
 
Table 1. Gradient elution steps 
Time (minutes) %Water (A) %Acetonitrile (B) 
0  100 0 
0.5 100 0 
4.5 90 10 
6 0 100 
6.5 0 100 
6.51 100 0 
7 100 0 
Ionisation, detection and quantification of cycloserine and IS was achieved on Xevo® 
TQ MS triple quadrupole tandem mass spectrometer equipped with electrospray 
ionisation source operating in positive ion mode. The mass spectrometer performed 
the detection of cycloserine and IS using multiple reaction mode (MRM) with the 
transition (precursor → product) of 103 →75 m/z for cycloserine and 260.2 →183 m/z 
for IS. The operating parameters used were set as follows: capillary voltage, 3.5 V; 
cone voltage, 15 V; collision energy range, 7-15 eV; source temperature, 140 ⁰C; 
desolvation temperature, 400 ⁰C; desolvation gas, 800 L/h and cone gas, 50 L/h. 
5.1.4 Preparation of stock solutions, quality controls and calibration standards 
Stock solution of cycloserine (1000 µg/mL) was prepared by dissolving accurately 
weighed 10.0 mg cycloserine in 10 mL of methanol. The stock quality control (QC) 
cycloserine solution with concentration of 800 µg/mL was prepared by dissolving 8.0 
mg of cycloserine in 10 mL of methanol. The IS stock solution with a concentration of 
100 µg/mL was prepared by dissolving 10 mg of propranolol in 100 mL of methanol. 
These solutions were kept at -80 ⁰C. 
The stock solution of cycloserine was appropriately diluted with methanol in order to 
make eight concentrations of standard working solution (500, 250, 50, 10, 2, 1, 0.5, 
0.1 µg/mL). Calibration standards were prepared by spiking 100 µL of each standard 
working solution to 900 µL of blank plasma. In this way, eight concentrations (50, 25, 
5, 1, 0.2, 0.1, 0.05, 0.01 µg/mL) for the calibration standard curve were prepared. The 
QC working standard solution was prepared by appropriate dilution of stock QC 
solution with methanol to 400, 100 and 5 µg/mL. The QC samples were prepared at 
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concentrations of 40, 10 and 0.5 µg/mL for high QC, medium QC and low QC, 
respectively, by spiking 100 µL of each QC working solution with 900 µL of blank 
plasma. The IS solution was further diluted with methanol to the concentration of 0.01 
µg/mL. 
5.1.5 Plasma sample pre-treatment  
Extraction of cycloserine from the spiked plasma (calibration standard curve and QC 
samples) was achieved through plasma protein precipitation. To each 200 µL of spiked 
plasma, 800 µL of IS solution was added and vortex mixed for 1 minute. In order to 
separate the precipitate, the contents were centrifuged (13000rpm) for 10 minutes at 
2 ⁰C. Five hundred micro-litres (500 µL) of the supernatant were pipetted into a clean 
vial. A further 500 µL of water was added to the supernatant and vortex mixed. Finally, 
2 µL of this solution was injected onto the UPLC system. 
5.1.6 Method validation 
The bioanalytical method was validated according to the International Conference for 
Harmonisation and United States Foods and Drugs Administration guidelines for 
validation of analytical procedures (USFDA, 2013, ICH, 2005). The method was 
validated for sensitivity or limit of quantification, limit of detection, linearity, accuracy, 
precision, recovery, carry-over, matrix effect and stability.  
5.1.7 Analysis of patient’s plasma samples 
Plasma cycloserine (terizidone metabolite) concentration was determined in 78 drug-
resistant tuberculosis patients treated with 750 mg terizidone daily dose and other anti-
tuberculosis drugs. The study was approved by the ethics committees of University of 
Cape Town (Ref: 777/2014) and University of the Western Cape (Ref: 07/6/12). 
Frozen patients’ plasma samples were left to thaw at room temperature and vortex 
mixed before pipetting. To every 200 μL of plasma, 800 μL of IS were added and 
vortex mixed for 1 minute. The procedure for the rest of the patients’ plasma sample 
preparation was same as the calibration standards. The bioanalytical run consisted of 
the processed sample plasma without IS and terizidone, processed plasma with IS 
only, calibration standards, processed patient samples and QC samples. 
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5.2 RESULTS  
5.2.1 Chromatographic and mass spectrometry conditions optimisation 
In order to optimise the separation efficiency and chromatographic peak shape of the 
analyte and the IS, several mobile phase compositions, the flow rate and different C18 
columns were employed. Acetonitrile and water, both acidified with 0.1% formic acid 
were found to be the best mobile phases with gradient composition shown in Table 1. 
Additionally, the flow rate of 0.4 mL/min was found suitable for current method. The 
column, Acquity UPLC BEH C18 (2.1 mm x 100 mm, 1.7 µm), was tried but the analyte 
eluted quite early. Separation of cycloserine and IS was best achieved on a 
Phenomenex KinetexTM PFP C18 (2.1 mm x 100 mm, 2.6 µm) reversed-phase column 
as it is ideal for separation of polar compounds (Figure 2).  
Using electrospray ionisation in positive mode, the protonated precursor ions [M+H]+ 
of cycloserine and propranolol that were dominant had m/z ratios of 103 and 260.2, 
respectively. After the conditions for fragmentation were optimised with collision 
energy in the range 7-15 eV, the most abundant and stable ions in the product spectra 
were observed at m/z ratios of 75 and 183 for cycloserine and propranolol, 
respectively. Other parameters for ionisation were optimised to obtain highest, stable 
and consistent signal intensity for cycloserine and propranolol. 
 
Figure 2. Chromatograms of cycloserine and propranolol with retention times at 0.52 minutes 
and 5.8 minutes, respectively. 
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5.2.2 Method validation 
5.2.2.1  Sensitivity and limit of detection 
Sensitivity was the lowest cycloserine concentration (lower limit of quantification–
LLOQ) that was measured with acceptable precision and accuracy. The lowest 
concentration of the calibration standards was determined to be 0.01 µg/mL as it had 
a precision of 19.3% (percentage relative standard deviation–%RSD) and accuracy of 
98.7% (Table 3). This was within the acceptable precision of not more than 20% and 
accuracy within 80 – 120% (USFDA, 2013).  
The limit of detection (LOD) based on the calibration curve, was calculated using the 
formula (1): 
𝐿𝑂𝐷 = 3.3𝜎/𝑆   (1) 
where σ was the standard deviation of the Y-intercepts of the regression equations 
shown in Table 2. Similarly, S was the average of the slopes of the regression 
equations. The value of the LOD was 0.004 µg/mL. 
5.2.2.2  Linearity 
The eight-point standard calibration curve was constructed by ploting cycloserine 
nominal concentrations on the X-axis against peak area ratios of cycloserine and IS 
on the Y-axis (response). The weighting factor of 1/x improved the linear regression 
fit. Linearity was assessed statistically by fitting the data (nominal concentration and 
response) to a linear regression model by method of least squares. The regression 
equations constructed from six replicate bioanalytical runs of the eight calibration 
standards are shown in Table 2 together with the corresponding coefficient of 
determination values and the sum of residuals. The average coefficient of 
determination and correlation coefficient was 0.9994 and 0.9997, respectively. 
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Table 2. Bioanalytical method linearity parameters 
Run number R-square (r2) Linear equation Residual sum of squares  
1 0.9998 𝑌 = 4.202𝑥 + 0.0604 0.00069 
2 0.9998 𝑌 = 4.161𝑥 + 0.0511 0.00107 
3 0.9999 𝑌 = 4.244𝑥 + 0.0536 0.00093 
4 0.9996 𝑌 = 4.301𝑥 + 0.0489 0.00141 
5 0.9998 𝑌 = 4.215𝑥 + 0.0578 0.00022 
6 0.9989 𝑌 = 4.207𝑥 + 0.0621 0.00209 
5.2.2.3  Accuracy and precision 
Five replicate values from the analyses of LLOQ, low QC, median QC and high QC 
were employed to calculate accuracy of the assay. The accuracy was estimated as 
the percentage ratio average (five replicates) of the back-calculated concentrations 
and the nominal concentration. The accuracy ranged from 98.7 – 116% and 99 – 117% 
for within-run analysis and between-run analysis, respectively (Table 3). Precision 
(%RSD) was calculated as the percentage ratio of the standard deviation and the 
mean of the replicates analysed on same day (within-run) and different days (between-
run). The within-run precision ranged between 3.7 and 19.3% while between-run 
precision was in the range 2.6 – 15% (Table 3). The accuracy and precision was within 
the accepted range (USFDA, 2013). 
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Table 3. Within-run and between-run accuracy and precision of the LLOQ, low QC, 
median QC and high QC assay. 
Nominal concentration 
(µg/mL) 
Mean 
concentration  ± SD 
(µg/mL) 
Accuracy (%) Precision 
(%RSD) 
Within-run analysis    
0.01 0.0098 ± 0.002 98.7 19.3 
0.5 0.58 ± 0.062 114.6 10.8 
10 9.94 ± 0.697 99.4 7 
40 40.48 ±1.48 101.2 3.7 
Between-run analysis     
0.01 0.012 ± 0.002 117.3 15 
0.5 0.57 ± 0.03 111 5.2 
10 10.3 ± 0.674 103 6.5 
40 39.6 ± 1.06 99 2.6 
SD, Standard deviation 
5.2.2.4  Carry-over and matrix effect 
The carry-over was assessed by injecting the highest concentration of the calibration 
standard (50 µg/mL) followed by a blank sample. A response of 238.874 was read 
after injection of 50 µg/mL and 0.00677 after injection of blank sample. The blank 
sample response corresponded to cycloserine concentration of 0.0021 µg/mL and was 
below the LLOQ.  
The matrix effect was evaluated by comparing the instrument response (peak area) of 
cycloserine and IS that was prepared in methanol and the one spiked in plasma. The 
average ratios of the peak area of cycloserine spiked in plasma to the one prepared 
in methanol were 0.9927 and 1.003 for low QC and high QC, respectively. Similarly, 
the average IS ratios were 0.9961 and 1.01. These results show that the effect of 
plasma (matrix) on the ionization of both cycloserine and IS was not significant.  
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5.2.2.5  Stability and recovery 
The analyte stability was evaluated according to the situations that were expected to 
be experienced during patient plasma sample processing and analysis (USFDA, 
2013). These situations were freeze-thaw of at least one cycle and stability of 
processed samples in the autosampler for maximum of 24 hours. The mean 
cycloserine concentration for the low QC and high QC after three freeze-thaw cycles 
was almost close to the nominal concentration. Nevertheless, the mean concentration 
of the processed samples that were stored at 2 – 8 ⁰C dropped by 11.9 and 1.75% for 
low QC and high QC, respectively, after 48 hours. The mean accuracy was 88.1 and 
98.3% while precision was 9.1 and 3.7% (RSD) the low QC and high QC, respectively. 
Recovery was determined by comparing instrument response of the analyte that was 
prepared in the solvent with analyte extracted from plasma (USFDA, 2013). The 
percentage recovery was in the range 88.7 – 91.2 for both low and high QC. 
5.2.3 Application of bioanalytical method in pharmacokinetic study 
Seventy-eight patients participated in the study after signing informed consent form. 
They provided 608 plasma samples, which were analysed for cycloserine as a 
metabolite of terizidone. The mean and median concentrations were 2.1 ±1.5 µg/mL 
and 1.9 (0.01 – 8.2) µg/mL, respectively. The distribution of the cycloserine 
concentration in shown in Figure 3. 
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Figure 3. Distribution of cycloserine concentrations in drug-resistant tuberculosis patients. 
5.3 DISCUSSION 
Protein precipitation was the preferred method of analyte (cycloserine) extraction from 
plasma as it is simple, fast and inexpensive (Sargent, 2013). The two-fold dilution of 
the supernatant with water and five-fold in protein precipitation procedure ensured also 
the dilution of interfering compounds. This procedure reduced the matrix effect (Mao 
et al., 2017). 
In the chromatographic separation, the initial 100% aqueous phase favoured the 
elution of cycloserine first as it is more polar than the IS. Subsequently, the gradual 
reduction of the aqueous phase or gradual increase of the organic phase in the second 
step of the gradient favoured the elution of the IS. The excellent peak shape, better 
separation and reproducibility (Figure 2) resulted from the combined C18 and 
pentafluoropheny (PFP) functionality through pi-pi, hydrogen bonding, dipole-dipole 
and hydrophobic interactions. Hence, the PFP C18 (2.1 mm x 100 mm, 2.6 µm) 
reversed-phase column was the best of the columns that were tried.  
The carry-over effect (0.0021 µg/mL), although minimal, was rather expected because 
cycloserine molecule is polar and has affinity for pentafluoropheny moiety (stationary 
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phase component). Hence, it remained stuck in the column but was gradually eluting 
with each run. On the other hand, the calibration curve was linear (ICH, 2005) over the 
concentration range 0.01 – 50 µg/mL as the coefficient of determination value and the 
sum of the residuals was approximatelty one and zero, respectively. 
Furthermore, our method had a better sensitivity of 0.01 µg/mL than a previously 
reported UPLC-MS/MS method (Han et al., 2013) with 0.5 µg/mL. Hence, it was 
suitable to measure low concentrations of cycloserine as a metabolite of terizidone in 
patients who were slow metabolisers. The method was successfully used to determine 
plasma concentrations of cycloserine in a population pharmacokinetic study of patients 
with drug-resistant tuberculosis hospitalised for intensive phase of treatment. 
5.4 CONCLUSION 
The simple, sensitive and reliable UPLC-MS/MS method was developed and validated 
for analysis of cycloserine in plasma of patients with drug-resistant tuberculosis. The 
validation parameters indicated that the method was linear, sensitive, stable, precise 
and accurate. The method is suitable for pharmacokinetic studies as sample 
processing is relatively simple and does not require use of expensive chemicals.
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Chapter Six 
 
In this chapter, a research paper entitled: 
“Steady-state Population Pharmacokinetics of Terizidone and its Metabolite 
Cycloserine in Patients with Drug-resistant Tuberculosis” 
is presented. It was published as an original article in the British Journal of Clinical 
Pharmacology, 2019: 85:1946–1956. https://doi.org/10.1111/bcp.13975. It has been 
re-used in this thesis with permission from the publisher (John Wiley & Sons, Inc. 
license number 4632450146888). The Copyright license agreement is included as 
Appendix 4. 
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Aims: Despite terizidone being part of the second‐line recommended drugs for
treatment of drug‐resistant tuberculosis (DR‐TB), information on its pharmacokinetics
is scarce. The aim of this study was to describe the steady‐state population pharma-
cokinetics (PPK) of terizidone and its primary metabolite cycloserine in patients with
DR‐TB and determine the effect of patient characteristics.
Methods: This clinical study involved 39 adult DR‐TB patients admitted to
Brewelskloof Hospital in Cape Town, South Africa for intensive treatment phase.
Blood samples were collected at predose and 0.5, 1, 2, 3, 3.5, 4, 8, 16 and 24 hours
after drug administration. The estimation of PPK parameters was performed using
nonlinear mixed‐effects modelling software Monolix 2018R1. Free‐fat mass was used
to perform allometric scaling on disposition parameters.
Results: A 1‐compartment model best described the pharmacokinetics of
terizidone and cycloserine. A modified transit compartment model described the
absorption of terizidone. The parameters of terizidone model were mean transit time
(1.7 h), absorption rate constant (2.97 h−1), apparent volume of distribution (Vp/F:
13.4 L) and apparent total clearance (0.51 L h−1). In the joint model, apparent fraction
of terizidone converted to cycloserine was 0.29 while apparent clearance of
terizidone via other routes and apparent cycloserine clearance was 0.1 L h−1 and
2.94 L h−1, respectively. Serum albumin had significant effect on Vp/F.
Conclusions: The developed PPK model described well the concentration–time
profile for terizidone and cycloserine in DR‐TB patients. High albumin concentration
was associated with low Vp/F.
KEYWORDS
cycloserine, drug‐resistant tuberculosis, population pharmacokinetics, terizidone
1 | INTRODUCTION
Drug‐resistant tuberculosis, which includes rifampicin mono‐resistant
and multidrug‐resistant tuberculosis, is a persistent global threat and
is linked to inadequate tuberculosis treatment.1,2 Usually, the
suboptimal drug treatment influences spontaneous mutations in the
Mycobacterium tuberculosis chromosomal genes, which lead to the
emergence of resistant strains.3 To prevent further drug resistance, a
multidrug treatment regimen consisting of 5–7 drugs is used in the
treatment of drug‐resistant tuberculosis.4
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Terizidone, a condensation product of two cycloserine molecules,
is one of the medicines used to treat drug‐resistant tuberculosis.5,6
Information on how terizidone is metabolised into cycloserine and
the enzymes involved is not available in literature. Nevertheless, it
seems to undergo hydrolysis into cycloserine presystemically.7
Terizidone and cycloserine exert their respective antibacterial effect
by disrupting the synthesis of peptidoglycan needed for bacterial cell
wall formation through inhibition of D‐alanine ligase and L‐alanine
racemase.8 Terizidone is a potential drug for treatment of extra‐
pulmonary tuberculosis9 and has been reported to have fewer central
nervous system side effects than cycloserine and well tolerated in
patients on dialysis.10,11 A recent study indicated that both terizidone
and cycloserine were clinically effective in the intensive treatment
phase of drug‐resistant tuberculosis.12
Despite terizidone being recommended and currently used in the
treatment of drug‐resistant tuberculosis,4 information on its pharma-
cokinetics in literature is hardly found or poorly described. There
appears to be only one study published in which terizidone and cyclo-
serine pharmacokinetics were compared after a single‐dose adminis-
tration of each drug in tuberculosis patients.13 After oral
administration of 250–750 mg, terizidone reaches maximum concen-
tration within 3 hours with absorption rate constant (ka) in the range
1.17–1.36 h−1. The distribution volume is high, ranging between 113
and 246 L, while clearance is in the range 2.49–6.4 L h−1. Thirty‐nine
percent of the administered dose is excreted in urine after 30 hours.13
Terizidone plasma and urine concentrations in this study were not
measured but estimated based on cycloserine using colorimetric
method.13 By contrast, the population pharmacokinetics of cycloser-
ine in multidrug‐resistant tuberculosis patients have been described14
as well as noncompartmental pharmacokinetics in which cycloserine
was measured as terizidone metabolite.15 Cycloserine reaches maxi-
mum concentration within 2–3 hours with ka of 0.135 h−1 after oral
daily dose of 500–1000 mg. It is widely distributed in most body fluids
and tissueswith distribution volume of 10.5 L. Its clearance is 1.38 L h−1
and primarily eliminated via renal route with 50–70% excreted
unchanged within 12–24 hours.14,16 The primary and secondary phar-
macokinetic parameters of terizidone at steady state in drug‐resistant
tuberculosis patients are still unknown.
The objective of this study was to describe the population
pharmacokinetics of terizidone and cycloserine at steady state in
patients with drug‐resistant tuberculosis and assess the influence of
patient characteristics on pharmacokinetic parameters. We also
estimated the associated secondary pharmacokinetic parameters.
2 | METHODS
2.1 | Study design
This was a non‐randomised observational clinical study involving adult
patients admitted for intensive treatment phase of drug‐resistant
tuberculosis at Brewelskloof Hospital, Western Cape province, South
Africa. All patients were taking second‐line anti‐tuberculosis drugs
such as pyrazinamide, ethionamide, kanamycin, moxifloxacin or
ofloxacin, and ethambutol in addition to terizidone. In patients with
tuberculosis monoresistant to rifampicin, isoniazid was added to their
treatment. The doses were administered according to the local treat-
ment guideline for management of drug‐resistant tuberculosis.17
The patients included in this study were on anti‐tuberculosis
treatment for at least 2 weeks and had consented to participate in
the study. Patients were excluded from the study if they requested
so, were pregnant, breast‐feeding, severely dehydrated or intolerant
to terizidone. The demographic information was captured from
patients on the day of the study while medical and treatment history
was obtained from patients' folders. The ethics committees of the
University of the Western Cape (Ref: 07/6/12) and University of
Cape Town (Ref: 777/2014) approved this study. The patients' infor-
mation was treated with confidentiality and the study was conducted
in conformity with the principles outlined in the declaration of
Helsinki.18
2.2 | Pharmacokinetic blood sampling
The patients were in fasting state from 22:00 hours prior to the
morning of the blood‐sampling day. Using an intravenous catheter
placed in a vein of the forearm, 5 mL of blood from each patient
was collected in heparinised tubes at baseline (predose) and at 0.5,
1, 2, 3, 3.5, 4, 8, 16 and 24 hours after drug administration. After
centrifugation, the plasma was stored at −80°C until the date of
analysis. Other blood samples were also collected for renal and liver
function tests, virological and immunological tests. Patients then took
their usual dose of anti‐tuberculosis medications, including terizidone,
and the time was noted. Human immunodeficiency virus (HIV)
coinfected patients also received antiretroviral drugs as prescribed.
Patients were then allowed to eat and drink as usual.
What is already known about this subject
• Single‐dose pharmacokinetics of terizidone.
What this study adds
• The study outlines the first description of population
pharmacokinetics of terizidone and cycloserine at
steady state in drug‐resistant tuberculosis patients with
and without human immunodeficiency virus infection.
• The study characterises for the first time the secondary
pharmacokinetic parameters of terizidone at steady state.
• The first description of terizidone fraction undergoing
biotransformation into cycloserine and the influence of
serum albumin on apparent volume of distribution of
terizidone.
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2.3 | Plasma quantification of terizidone and
cycloserine
Plasma concentration of terizidone was analysed using high‐
performance liquid chromatography–UV method. It was extracted
from plasma using protein precipitation method. The average inter‐
and intraday precision was 3.3 and 7%, respectively, while the mean
accuracy was 107%. Calibration curves were linear with coefficient
of determination ranging between 0.9988 and 0.9999. The lower limit
of quantification and limit of detection was 3.125 and 0.78 μg mL−1,
respectively.19 Cycloserine concentrations were analysed using ultra‐
performance liquid chromatography–tandem mass spectrometry
method and validated according to the international guidelines.20
Extraction was achieved through plasma protein precipitation with
propranolol as internal standard. The mean inter‐ and intraday preci-
sion was 10.2 and 7.3%, respectively. The inter‐ and intraday accuracy
was 103.8 and 108.7%, respectively. The curves were linear over the
concentration range of 0.01–50 μg mL−1 with mean coefficient of
determination of 0.9994. The quantification and detection limits were
0.01 and 0.004 μg mL−1, respectively, while the carry‐over was
0.0021 μg mL−1. The matrix effect was insignificant. Cycloserine was
stable after 3 freeze–thaw cycles and extraction efficiency ranged
between 68.7 and 71.2%.
2.4 | Pharmacokinetic modelling
At the time of pharmacokinetic blood sampling, all patients had
already achieved steady‐state concentration for terizidone. The
previous dose of terizidone was administered 24 hours before the
sampling day. Therefore, the predose sampling time of 0 hours was
set to 23.9 hours for modelling purposes. Conversion of concentration
from μg mL−1 to μmol L−1 (molar units) was performed by using molar
mass of 302.3 g mol−1 and 102.1 g mol−1 for terizidone and cycloser-
ine, respectively. The doses for terizidone were also converted from
mg to μmol.
The population pharmacokinetic parameters were estimated using
nonlinear mixed‐effects modelling in Monolix 2018R1 software.21 The
software utilises stochastic approximation expectation maximization
algorithm22 to carry out parameter estimations. The likelihood and
Fisher information matrix were computed using importance sampling
and stochastic approximation, respectively. Selection of the base
model was guided by the visual inspection of diagnostic plots, change
in the objective function value (OFV: −2 * loglikelihood), plausibility and
precision of the parameter estimates (percentage relative standard
error–%RSE).
We performed modelling in 2 parts. In the first part, only terizidone
concentration–time profile was modelled. Based on the visual
inspection of terizidone concentration–time profile using Datxplore
interface of Monolix 2018R1, 1‐ and 2‐compartment models were fit
to the data. Absorption process was modelled using lag‐time or transit
compartment model23 and assessed if it improved the model fit. In the
case of the transit compartment being over‐parameterised,
modification was performed by setting ka equal to transit rate con-
stant (Ktr; http://mlxtran.lixoft.com/examples/transit‐compartments‐
weibull‐absorption/).
In the second part, terizidone and cycloserine concentration–time
profiles were modelled jointly. Terizidone model was modified in order
to link it to cycloserine compartment. We assumed that terizidone did
not undergo first‐pass metabolism but was eliminated by biotransfor-
mation into cycloserine and other routes. Additionally, oral bioavail-
ability ( F ) was assumed to be one. The fraction (Fm) of terizidone
that is converted into cycloserine is unknown and unidentifiable.
The clearance of terizidone by other routes is also unidentifiable. Sim-
ilarly, the apparent volume of distribution of cycloserine (Vm/F) is
unidentifiable, as the dose was not administered directly. To circum-
vent this problem, we decided to fix Vm/F to the literature value of
10.5 L.14 This decision allows Fm to be identified and to distinguish
between terizidone clearance via biotransformation and other
routes.24,25 It is worth noting that Fm is not the true fraction but
apparent fraction.26 Another way of dealing with parameter
identifiability problem is to set the volume of the parent drug equal
to metabolite volume, fixing metabolite volume equal to 1 or fixing
Fm to any value between zero and 1. However, we chose not to
undertake these options.
Proportional and combined (additive and proportional) error
models were explored to model residual unexplained variability. The
between‐subject variability (BSV) model described the random
variation in population pharmacokinetic parameters. We assumed that
these parameters were log‐normally distributed.
2.5 | Covariate model
After the base model was selected using the criteria in previous sec-
tion, we investigated the effects of covariates on pharmacokinetic
model parameters. The total body weight (TBW), free‐fat mass27
(FFM) or body mass index was used as body size descriptor. In order
to adjust for the expected effect of body size, allometric scaling was
performed on clearance and volume parameters. The exponents were
either fixed to 0.75 for clearance and 1 for volume28 or estimated.
Other covariates explored were age, sex, HIV status, alanine amino-
transferase, aspartate transaminase, total bilirubin, TBW creatinine
clearance and FFM creatinine clearance. Creatinine clearance was
calculated using Cockcroft–Gault formula.29 A covariate was selected
if it was pharmacologically plausible; a correlation existed between a
covariate and the random effects of the predicted individual param-
eters. Retention of the covariate in the model was based on statisti-
cal significance (P ≤ .05 using Wald test), a decrease in OFV and
BSV. Covariates, normalised by the typical population median value,
were added in the model one at a time in log‐linear fashion. The
relationship between a pharmacokinetic value (θi) and continuous
covariate (covi) and of an i‐th individual was expressed as shown in
equation 1:
θi ¼ θpop* coviCOVmedian
 βθi
* e
ηi (1)
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where θpop represented the typical population pharmacokinetic value
and COVmedian the population median value of the continuous covar-
iates. The random effect associated with the i‐th individual was
denoted by ηi where ηi ≈ N(0,ω
2). The factor describing the effect
of a continuous covariate on θi was denoted by βθi. The relationship,
in the case of the categorical covariates was expressed as shown in
equation 2:
θi ¼ θpop *eβθi;cat cat¼n½  *eηi (2)
where βθi,cat[cat = n] denoted the difference in parameter (θi)
between an individual belonging to group n and the reference group.
Correlations among random effects of estimated individual parame-
ters were then investigated and significant ones were estimated as
population parameters.
2.6 | Model evaluation
The model was evaluated visually by inspection of the diagnostic plots
such as individual‐ and population predicted vs observed concentra-
tions, individual‐weighted residuals vs time and predicted concentra-
tions. The visual predictive checks for both terizidone and
cycloserine were inspected for possible model misspecification.
The distribution of parameter estimates randomly sampled from the
conditional distribution30 were evaluated in order to ensure that the
assumption of normality was met. We also performed a bootstrap pro-
cedure of 250 runs using Monolix software aided by Rsmlx (R Speaks
‘Monolix’) R package (http://rsmlx.webpopix.org), in order to evaluate
the robustness of the final joint model.
2.7 | Secondary pharmacokinetic parameters
The other pharmacokinetic parameters for terizidone and cycloserine
were calculated using MLXTRAN coded formulae in Monolix as shown
in Appendix A. The area under the concentration–time curve up to 24
hours (AUC0‐24h) and half‐life were calculated by integration of the
concentrations predicted from the final joint pharmacokinetic model
without covariates and formulae, respectively. The maximum plasma
concentration (Cmax) and time to reach Cmax (Tmax) were obtained from
the output file of the predicted individual concentrations. Finally, the
clearance of terizidone resulting from biotransformation into cycloser-
ine was calculated from the individual predicted estimates of
terizidone apparent volume of distribution (Vp/F), Fm and biotransfor-
mation rate constant. Model‐based simulations of the distributions of
AUC0‐24h and Cmax were performed across 3 weight bands specified in
the local treatment guideline17 using current dose (750 mg daily). A
dosing schedule was proposed that would normalise exposure across
weight bands using Monte‐Carlo simulations.
3 | RESULTS
Thirty‐nine patients including 27 HIV infected and 20 females partici-
pated in this study. Thirty‐eight patients received a daily dose of
750 mg of terizidone while 1 patient received 500 mg. In total, they
provided 571 plasma concentrations, of which 272 were for
terizidone. The average number of plasma samples per patient was 7
and 8 for terizidone and cycloserine, respectively. The summary of
patients' demographic characteristics are displayed inTable 1. The plot
of the concentration vs time of the original data for terizidone and
cycloserine is shown in Figure 1.
3.1 | Terizidone pharmacokinetic model
The base model consisted of a 1‐compartment pharmacokinetic model
with first‐order absorption and linear elimination. A combined additive
and proportional error model best modelled the residual unexplained
variability in terizidone concentration. A lag‐time parameter was
added to describe absorption delay but did not improve the model
fit (OFV = +4). When a transit compartment model was used instead,
resulted in worse fit (OFV = +8.52) than the base model. Additionally,
the ka was overestimated and thus not plausible besides %RSE could
not be estimated. The transit compartment model was then modified
by setting Ktr equal to ka. This modification resulted in improved
model fit (OFV = −39.1) and good parameter precision (Table 2).
Therefore, the final terizidone model had the following parameters:
mean transit time (Mtt), ka, Vp/F and apparent total clearance (Cltot/F).
TABLE 1 Summary of patients' demographic characteristics
Variable Value
Sample size (n) 39
Sex
Female (n) 20
Male (n) 19
Age (years) 32 (17–56)a
Total body weight–TBW (kg) 51.4 (32.4–71)a
Free fat mass–FFM (kg) 39.8 (24.8–51)a
Body mass index (kg m−2) 18.4 (12.4–26.1)a
Alanine aminotransferase (IU L−1) 11 (4–46)a
Aspartate transaminase (IU L−1) 33 (17–109)a
Albumin (g L−1) 32 (15–48)a
TBW creatinine clearance (ml min−1) 83 (34.5–128)a
FFM creatinine clearance (ml min−1) 60.4 (26.8–106)a
Total bilirubin (μmol L−1) 7 (2–24)a
Human immunodeficiency virus status
Infected (n) 27
Uninfected (n) 12
CD4 count (cells μl−3) 227 (9–1243)a
Viral load (copies mL−1) 3279 (42–4 331 310)b
aMedian and range.
bMedian and range from 19 patients who had their viral load above 40
copies mL−1 while the viral load from 8 patients was below 40 copies mL−1.
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Allometric scaling using FFM, TBW and body mass index was per-
formed on Vp/F and Cltot/F. The FFM was found to be the best
descriptor of body size as it was associated with the lowest OFV. Allo-
metric scaling using FFM after fixing exponent to 1 and 0.75 on Vp/F
and Cltot/F resulted in model improvement (OFV = −90.04) and this
explained 13.5 and 5% of the variation in Vp/F and Cltot/F, respec-
tively. The covariates, sex, FFM creatinine clearance and HIV status
had significant effect on Cltot/F, while albumin had significant effect
on Vp/F. However, when all significant covariates were included in
the model, only albumin remained significant on Vp/F and led to
improved model fit (OFV = −11.9; p = 0.0062). The variation explained
by albumin in Vp/F was 43.2%. There were no significant correlations
found among parameter random effects. The summary of the popula-
tion pharmacokinetic parameters of terizidone are shown in Table 2.
3.2 | Joint terizidone and cycloserine model
Terizidone final model was modified in order to incorporate a cyclo-
serine compartment as illustrated in Figure 2. The Cltot/F was divided
into apparent clearance of terizidone due to biotransformation into
cycloserine (Clpm = Cltot/Fm) and apparent clearance of terizidone
via other routes (Clp = Cltot/(1‐Fm)). A 1‐compartment model with
first‐order elimination best characterised cycloserine disposition. The
combined additive and proportional error model best described the
FIGURE 1 Observed concentration–time profiles for terizidone and
cycloserine
TABLE 2 Population pharmacokinetic parameters from terizidone
only model
Parameter Estimate %RSE
Mtt (h) 1.6 17.1
ka (h−1) 2.97 19.1
Vp/F a (L) 13.4 4.8
Cltot/F
a (L h−1) 0.51 10.9
Coefficient (effect) of albumin on Vp/F −0.61 30.3
Between‐subject variability (CV%)b
Mtt 82 18.3
ka 36.1 53.1
Vp/F 16 35
Cltot/F 64 13
Residual error
Additive (μmol L−1) 13.6 31
Proportional 0.13 20
aAllometrically scaled parameters using FFM by fixing exponents to 1 and
0.75 on Vp/F and Cltot/F, respectively.
bCoefficient of variation percentage calculated as
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
e SDð Þ
2
− 1
p 
*100
where SD is the estimated standard deviation.
%RSE, percentage relative standard error; Mtt, mean transit time; ka,
absorption rate constant; Vp/F, apparent volume of distribution; Cltot/F,
apparent total clearance of terizidone.
FIGURE 2 Schematic diagram for the joint pharmacokinetics model
of terizidone and cycloserine. Mtt, mean transit time of terizidone
from ingestion to its absorption; Ad, amount of terizidone at the
absorption site; ka, absorption rate constant of terizidone; Vp/
F, apparent volume of distribution of terizidone; Clp = Cltot/(1‐
Fm), clearance of terizidone via other routes; Fm, apparent fraction of
terizidone converted to cycloserine; Cltot/F, apparent total clearance
of terizidone (Clp + Clpm), Vm/F (10.5 L), apparent volume of
distribution of cycloserine; Clm/F, apparent clearance of cycloserine
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residual unexplained variability in cycloserine concentration. Allome-
tric scaling on apparent clearance of cycloserine (Clm/F) using FFM
and fixing the exponent to 0.75 slightly improved the joint model with
OFV change of −0.82. The variation in Clm/F explained by this scaling
was 17%. After scaling of Clm/F with FFM, no covariates were found
significant on Fm, Clp and Clm/F. The values for Mtt, ka, and Vp/F in
the terizidone and joint model were not exactly the same but similar.
The joint model was described by the following system of ordinary
differential equations 3–5:
dAd=dt ¼ −ka*Ad (3)
dApc=dt ¼ ka*Ad − Cltot= 1 − Fmð Þð Þ=Vp*Apc − Cltot= Fmð Þ=Vp*Apc
(4)
dAm=dt ¼ Cltot= Fmð Þ=Vpð Þ*Apc − Clm= Fð Þ=10:5*Am (5)
The amount of terizidone at the absorption site and central
compartment was denoted by Ad and Apc, respectively, with ka as
the absorption rate constant. The amount of cycloserine formed from
terizidone metabolism was denoted as Am.
The final joint model had the parameters:Mtt, ka, Vp/F, Clp, Fm and
Clm/F (Table 3). The final individual models of Vp/F, Clp and Clm/F
belonging to an i‐th individual were described as follows 6–8:
Vp
Fi
¼ 14*
FFMi
39:8
 1
*
Albumini
32
 −0:51
*e
ηi (6)
Clp ¼ 0:1*
FFMi
39:8
 0:75
*e
ηi (7)
Clm
Fi
¼ 2:94*
FFMi
39:8
 0:75
*e
ηi (8)
3.3 | Model evaluation
The plots of individual predicted vs observed concentration for both
terizidone and cycloserine indicated that there was a good agreement
FIGURE 3 Population and individual
predicted vs observed concentrations for
terizidone A, and cycloserine B
MULUBWA AND MUGABO 1951
86http://etd.uwc.ac.za/
between predicted and observed concentration (Figure 3). Similarly,
Figure 4 showed that there was no bias observed in the plots of
individual‐weighted residuals vs time and predicted concentration.
The visual predictive checks for the joint model are shown in
Figure 5. Most of the observed data points lay within 90% prediction
interval (generated from 1000 simulations) except for the 95th percen-
tile of cycloserine visual predictive checks that showed some over pre-
diction in variability. The bootstrap parameters in Table 3 were similar
to the ones estimated from the original data set. Therefore, the devel-
oped joint model described fairly the observed plasma concentration–
time profiles for terizidone and cycloserine.
3.4 | Secondary pharmacokinetic parameters
The secondary pharmacokinetic parameters for terizidone were Cmax,
Tmax, AUC0‐24h, half‐life and Clpm and for cycloserine were Cmax, Tmax,
AUC0‐24h and half‐life (Table 4). The MLXTRAN model file for Monolix
in Appendix A gives the code of how these parameters were
calculated. The simulated distributions of AUC0‐24h and Cmax
(Figure 6) show a decreasing trend in the median value across the 3
weight bands, 33–50 kg, 51–70 kg and > 70 kg, respectively.
Monte‐Carlo simulations showed that a terizidone daily (every
24 hours) dose of 750, 900 and 1200 mg achieved similar exposure
across the weight bands 33–50, 51–70 and > 70 kg, respectively.
The proposed dosing schedule is shown in Table 5.
4 | DISCUSSION
There is scarce information in the literature on pharmacokinetics of
terizidone although it is an old drug. In this study, we, for the first, time
developed a population pharmacokinetic model of terizidone and a
joint model (with cycloserine) at steady state in patients with drug‐
resistant tuberculosis. A 1‐compartment model with first‐order
absorption and elimination best described terizidone pharmacokinet-
ics. A modified transit compartment model described better the
absorption delay than the lag time, as the precision in the former
FIGURE 4 Individual‐weighted residuals vs
time and predicted concentrations for
terizidone A, and cycloserine B
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was better than the latter. Initially, addition of a lag time or transit
compartment to model the delayed absorption did not improve the
model fit. This indicated a possibility of over parameterisation for
the transit compartment model. When the number of parameters
were reduced from 3 to 2 by setting ka equal to Ktr, this resulted in
improved model fit. The average time (Mtt) it took from the ingestion
of terizidone to its absorption was about 102 minutes (1.7 hours). It
then underwent fast absorption with ka of 2.97 h−1. Within a median
Tmax of 4 hours, terizidone reached a Cmax of 239 μmol L
−1.
Adjusting for the effect of body size (allometric scaling) on Vp/F
and Cltot/F using FFM and fixing exponents, resulted in model
improvement. The FFM was the best descriptor of body size as it
was associated with the lowest OFV. As a result of this scaling, the
BSV in Vp/F and Cltot/F decreased by 13.5 and 5%, respectively. The
population estimates of the Vp/F and Cltot/F were thus estimated with
good precision. Serum albumin had significant effect on the Vp/F and
accounted for 43.2% of the variation in the Vp/F. Additionally, this
improved the model fit. The effect was in such a way that high serum
albumin concentration was significantly associated with low values
of Vp/F or vice versa. This phenomenon is well known as increased
drug binding resulting from increased serum albumin concentration
tend to decrease the volume of distribution.31,32 This effect of albumin
on Vp/F may have potential clinical impact on patients with hepatic
impairment.
The pharmacokinetic parameters (Mtt, ka and Vp/F) of the joint
model, although not exactly the same, were similar to those of
terizidone model. Additionally, these parameters were estimated with
good precision. In the joint model, it was clearly observed that the
FIGURE 5 Visual predictive checks of terizidone and cycloserine
generated from 1000 simulations. The shaded areas represent the
prediction interval at 5th, 50th and 95th percentiles (95% confidence
interval). The solid lines represent the empirical median of the 5th, 50th
and 95th percentiles. The observed data is represented by dots
TABLE 3 Terizidone and cycloserine population pharmacokinetic
parameters from a joint model
Parameter
Model estimate Bootstrap
Estimate %RSE Median
95% CI (lower,
upper)
Mtt (h) 1.43 14 1.01 0.92, 1.75
ka (h−1) 3.2 10.5 3.1 2.69, 3.4
Vp/F a (L) 14 11 13.4 12.4, 14.6
Clp a (L h−1) 0.1 12 0.08 0.05, 0.09
Fm 0.29 10 0.24 0.19, 0.33
Clm/F a (L h−1) 2.94 20.2 2.7 2.44, 3.01
Coefficient
(effect) of
albumin on
Vp/F
−0.51 54.9 −0.50 −0.73, −0.47
Between‐subject variability (CV%)b
Mtt 75 10 83 71.2, 96
Ka 46 28 48 43, 56
Vp/F 22 15 25 91, 27
Clp 52 16.1 46.2 44, 51
Fm 27 31.2 21.8 19, 29
Clm/F 189 11 171 162, 226
Residual error
Additive,
terizidone
(μmol L−1)
25 17.9 21 20, 24.4
Proportional,
terizidone
0.04 63.1 0.04 0.04, 0.05
Additive,
cycloserine
(μmol L−1)
0.29 33.6 0.3 0.22, 0.3
Proportional,
cycloserine
0.32 6.14 0.3 0.24, 0.31
aAllometrically scaled parameters using FFM by fixing exponents to 1 on
Vp/F and 0.75 on Clp and Clm/F.
bCoefficient of variation percentage calculated as
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
e SDð Þ
2
− 1
p 
*100
where SD is the estimated standard deviation.
%RSE, percentage relative standard error; CI, confidence interval; Mtt,
mean transit time; ka, absorption rate constant; Vp/F, apparent volume
of distribution; Cltot/F, apparent total clearance of terizidone; Fm, fraction
of terizidone that is converted into cycloserine; Clm/F, apparent clearance
of cycloserine.
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estimated Clp (0.1 L h−1) was lower than Clpm (0.47 L h−1). This implied
that terizidone clearance via biotransformation into cycloserine was
higher than clearance via other routes. The closeness of the sum value
of Clp and Clpm (0.57 L h−1) and Cltot/F (0.51 L h
−1) indicated that the
joint model was able to discriminate well between the Clpm driven by
Fm and Clp. On average, 29% of the total amount of terizidone in the
body was being converted to cycloserine, suggesting that 71% of the
remaining was eliminated via other routes. However, this was not
the absolute but apparent fraction, owing to the unavailability of urine
data. No covariates tested had significant effect on Clp, Fm and Clm/F.
Meanwhile, there was high BSV observed in Clm/F and Mtt, which
could not be explained by the covariates tested. The pharmacokinetic
parameters of terizidone in our study are different from the previously
reported,13 where blood was sampled after a single dose or before
steady state. In the previous study,13 Vp/F and Cltot/F were higher
(245.6 L, 6.4 L h−1) than in our study (13.4 L, 0.51 L h−1). Meanwhile,
in the study by Zitkova and Toušek,13 the observed average Cmax
resulting from 750 mg dose of terizidone was very different from
the Cmax that we simulated using their model (approximately 19 vs
6.1 μg mL−1, respectively). It is noteworthy that the method33 Zitkova
and Toušek13 used to determine terizidone concentrations was vali-
dated for cycloserine and not terizidone. In their study,13 terizidone
was not determined directly but estimated based on the cycloserine
concentration. Therefore, concentrations might have been inaccu-
rately estimated and lead to incorrect estimation of terizidone
pharmacokinetic parameters. These shortcomings associated with
determination of terizidone in Zitkova and Toušek's study13 may
explain the differences in Vp/F and Cltot/F in our study.
The precision at which pharmacokinetic parameters were esti-
mated in the joint and terizidone model was generally good. However,
the %RSE in the estimation of BSV in ka, proportional error estimate
and coefficient of albumin on Vp/F were slightly above 50%. There
was good agreement between observed and predicted concentrations
and the model predicted well the concentrations across all time points
as no bias was seen in the residual plots. The visual predictive checks
indicated that the joint model fitted well the observed terizidone and
cycloserine concentration–time data, as most of the observed data
overlapped with the simulated percentiles. Although the model
showed slight over prediction in the absorption phase, the bootstrap
parameters were comparable with those estimated from the original
data set. Therefore, the final joint model without covariates that was
used to estimate the Cmax, Tmax, AUC0‐24h, half‐life and Clpm was
appropriate.
TABLE 4 Summary of the secondary pharmacokinetic parameters of
terizidone and cycloserine
Pharmacokinetic parameters Median and range
Terizidone
Cmax (μmol L
−1) 239 (64.2–520)
Tmax (h) 4 (2–8)
AUC0‐24h (μmol h L
−1) 1635 (483–8954)
Half‐life (h) 17.8 (9–45)
Clpm (L h−1) 0.47 (0.05–1.88)
Cycloserine
Cmax (μmol L
−1) 24.1 (0.54–63.5)
Tmax (h) 8 (3–8)
AUC0‐24h (μmol h L
−1) 203 (3.6–99)
Half‐life (h) 2.49 (0.32–11.9)
Cmax, maximum plasma concentration; Tmax, time to reach Cmax; AUC0‐24h,
area under the concentration–time curve up to 24 hours; Clpm, apparent
clearance of terizidone due to biotransformation into cycloserine.
FIGURE 6 Box plots of simulated area under the concentration–
time curve up to 24 hours (AUC) and maximum plasma
concentration (Cmax) for the current recommended terizidone daily
dose of 750 mg stratified by weight band
TABLE 5 Proposed dosing schedule of terizidone across 3 weight
bands
Simulated exposure
Weight
band (kg) Dose (mg)a AUC0‐24h (μmol h L−1)b Cmax (μmol L−1)b
33–50 750 4929 (3694–6317) 278 (228–336)
51–70 900 5045 (3929–6392) 278 (227–335)
> 70 1200 5047 (3926–6381) 279 (228–335)
aDosed every 24 hours.
bValues expressed as median and interquartile range.
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The local treatment guideline for the management of drug‐resistant
tuberculosis17 recommends terizidone daily dose of 750 mg for
patients in the weight bands 33–50 and 51–70 kg and 750–1000 mg
for patients >70 kg. Although no information on the target AUC0‐24h
or Cmax for terizidone is available from the literature, model‐based sim-
ulations show that a 750 mg daily does not achieve similar AUC0‐24h or
Cmax across the 3 weight bands. Therefore, we propose a terizidone
daily dose of 900 and 1200 mg for patients in the weight bands
51–70 and > 70 kg, respectively. This would ensure the achievement
of a similar exposure in patients weighing 33–50 kg and taking
750 mg of the drug.
In conclusion, we report, for the first time the population pharma-
cokinetics of terizidone and its metabolite cycloserine in patients with
drug‐resistant tuberculosis. We characterised the secondary pharma-
cokinetic parameters of terizidone and cycloserine. High serum
albumin concentration was significantly associated with low Vp/F in
this patient population. The FFM was found to be the best descriptor
of body size and most ideal for body size effect adjustment. On
average, 29% of the terizidone amount in the body was converted into
cycloserine. The low Cltot/F or long half‐life supports once daily dosing
of terizidone in drug‐resistant tuberculosis patients.
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APPENDIX A
AUC computation of parent and metabolite for 1‐compartment model
with first‐order absorption and elimination with parameters Mtt, ka,
Vp, Cl, Fm and Clm using ODE.
[LONGITUDINAL]
input = {Mtt, ka, Vp, Cl, Fm, Clm}
PK:
depot (target = Ad, Mtt, Ktr = ka, ka)
EQUATION:
odeType = stiff
Vm = 10.5
kp = Cl/(Vp*(1-Fm))
kt = Cl/(Vp*Fm)
km = Clm/Vm
;Initial conditions
t_0 = −120
Ad_0 = 0
Apc_0 = 0
Am_0 = 0
;Differential equations
ddt_Ad = −ka*Ad
ddt_Apc = ka*Ad - kp*Apc - kt*Apc
ddt_Am = kt*Apc - km*Am
ddt_AUCp = 1/Vp * Apc
ddt_AUCm = 1/Vm * Am
if(t < 24)
AUC24p = AUCp
end
if(t < 48)
AUC48p = AUCp
end
AUC24_48p = AUC48p - AUC24p
if(t < 24)
AUC24m = AUCm
end
if(t < 48)
AUC48m = AUCm
end
AUC24_48m = AUC48m - AUC24m
;other PK parameters
T_HalfTZ = log(2)/(kp + kt)
T_HalfCS = log(2)/km
Cl_TZtrans = kt*Vp
Cp = Apc/Vp
Cm = Am/Vm
OUTPUT:
output = {Cp, Cm}
table = {AUC24_48p, AUC24_48m, T_HalfTZ, T_HalfCS,
Cl_TZtrans}
1956 MULUBWA AND MUGABO
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Abstract
Background and objectives The dosing of cycloserine and terizidone is the same, as both drugs are considered equivalent 
or used interchangeably. Nevertheless, it is not certain from the literature that these drugs are interchangeable. Therefore, 
the amount of cycloserine resulting from the metabolism of terizidone and the relationship with hepatic function were 
determined.
Methods This prospective clinical study involved 39 patients with drug-resistant tuberculosis admitted for an intensive 
phase of treatment. Cycloserine pharmacokinetic parameters for individual patients, like area under the curve (AUC), clear-
ance (CLm/F), peak concentration (Cmax) and trough concentration (Cmin), were calculated from a previously validated joint 
population pharmacokinetic model of terizidone and cycloserine. Correlation and regression analyses were performed for 
pharmacokinetic parameters and unconjugated bilirubin (UB), conjugated bilirubin (CB), albumin, the ratio of aspartate 
transaminase to alanine aminotransferase (AST/ALT), or binding affinity of UB to albumin (Kaf), using R statistical software 
version 3.5.3.
Results Thirty-eight patients took a daily dose of 750 mg terizidone, while one took 500 mg. The amount of cycloserine 
[median (range)] that emanated from terizidone metabolism was 51.6 (0.64–374) mg. Cmax (R2 = 22%, p = 0.003) and Cmin 
(R2 = 10.6%, p = 0.044) were significantly associated with increased CB concentration. Cmax was significantly associated with 
increased Kaf (R2 = 10.1%, p = 0.048), while high CLm/F was significantly associated with decreased AST/ALT (R2 = 21%, 
p = 0.003).
Conclusions Cycloserine is not interchangeable with terizidone, as amounts are lower than expected. Cycloserine may be a 
predisposing factor to the development of hyperbilirubinaemia, as CLm/F is affected by hepatic function.
 * Mwila Mulubwa 
 3579753@myuwc.ac.za; mwila.mulubwa@gmail.com
1 School of Pharmacy, University of the Western Cape, Private 
Bag X17, Bellville, Cape Town 7535, South Africa
Key Points 
Terizidone is not completely metabolised into cycloser-
ine in patients with drug-resistant tuberculosis.
Cycloserine and terizidone cannot be used interchange-
ably.
Cycloserine and terizidone exposure may be a predispos-
ing factor to the development of jaundice in patients with 
drug-resistant tuberculosis.
1 Introduction
Drug-resistant tuberculosis remains a public health crisis, and 
treatment success continues to be low, at 55% worldwide [1]. 
Cycloserine is among the recommended group C second-line 
drugs for treatment of drug-resistant tuberculosis [2]. One of 
its advantages is that it does not share cross-resistance with 
other anti-tuberculosis drugs in the regimen, although it is 
associated with neurological side effects [3]. Its antimycobac-
terial bacteriostatic effect is achieved through inhibition of the 
enzymes d-alanine ligase and alanine racemase, which are both 
essential for the biosynthesis of peptidoglycan, a bacterial cell 
wall component [4]. The susceptibility breakpoint is 64 µg/
mL, and efficacy is driven by the percentage of time the plasma 
concentration is above the minimum inhibitory concentration. 
Nevertheless, the doses likely to achieve bactericidal effect in 
patients could be neurotoxic, as they are high [5].
93http://etd.uwc.ac.za/
290 M. Mulubwa, P. Mugabo 
Terizidone, which is a condensation product of two 
molecules of cycloserine joined by a terephthalaldehyde 
moiety, is also part of the recommended group C second-
line drugs for treatment of drug-resistant tuberculosis [2, 
6]. The metabolism of terizidone has not been character-
ised. However, it is thought to convert into cycloserine 
and para-phthalate, likely by hydrolysis of imine groups 
pre-systemically [7, 8]. Terephthalaldehyde in humans 
has been shown to undergo quick metabolism into tere-
phalic acid, which is a more stable metabolite and read-
ily excreted in urine [9]. However, the enzymes involved 
in these metabolic processes are not known. The in vivo 
metabolism of cycloserine, a structural analogue of amino 
acid d-alanine [6], has not been characterised in humans. 
Meanwhile, in vitro studies show that d- or l-cycloserine 
in the presence of alanine racemase undergo racemisation 
followed by transamination to form a stable isoxazole by 
irreversible tautomerisation of the intermediate substrate, 
ketimine [10].
In patients with drug-resistant tuberculosis, a dose of 
250–500 mg of cycloserine administered orally twice daily 
is slowly absorbed, with an absorption rate constant of 
0.135 h−1, and reaches the average maximum plasma con-
centration of 22 µg/mL within 4 h [11]. It is widely dis-
tributed to most body fluids (bile, synovial fluid, breast 
milk, sputum) and tissues (lymphatic tissues and lungs) and 
crosses the placenta, with the apparent distribution of 10.5 L. 
Cycloserine apparent clearance is 1.38 L/h. It is primarily 
excreted in urine, with 50 and 70% excreted unchanged in 
12 and 24 h, respectively. The elimination half-life is 5.27 h. 
The between-subject variation in apparent clearance and dis-
tribution volume is 22.3 and 35.1%, respectively [11, 12].
Treatment of drug-resistant tuberculosis with a multid-
rug regimen consisting of cycloserine/terizidone and other 
second-line drugs is associated with adverse reactions 
[13]. Hepatotoxicity, nephrotoxicity and hypokalaemia 
are the most possible life-threatening adverse reactions 
that require alteration of the drug regimen or temporal 
withdraw [14]. Furthermore, mortality is high when hepa-
totoxicity is accompanied by jaundice, encephalopathy and 
ascites [15].
Cycloserine and terizidone are considered equivalent, and 
doses are currently used interchangeably [7, 8]. Owing to the 
unavailability of bioequivalence or mass balance studies of 
terizidone, the equivalence of dosing has not yet been estab-
lished [8]. The objective of this study was to determine the 
average amount of cycloserine that results from the metabo-
lism of terizidone in patients with drug-resistant tuberculo-
sis. We also assessed the potential effect of cycloserine and 
terizidone exposure on the incidence of hepatotoxicity or 
nephrotoxicity in these patients.
2  Methods
The details of the study design, including the study popula-
tion, drug administration, ethics, inclusion and exclusion 
criteria, and population pharmacokinetic modelling, have 
been described elsewhere [16]. Briefly, this was a prospec-
tive clinical study of patients admitted for intensive phase 
treatment of drug-resistant tuberculosis. They were taking 
500–750 mg of terizidone once daily, and other second-
line anti-tuberculosis drugs (ethionamide, pyrazinamide, 
moxifloxacin, ethambutol, isoniazid and kanamycin) were 
administered according to the local treatment guideline 
[17]. Blood for pharmacokinetics study was sampled at 
baseline and 0.5, 1, 2, 3, 3.5, 4, 8, 16 and 24 h after drug 
administration. Separate blood samples were also drawn 
for liver [total bilirubin, conjugated bilirubin, unconjugated 
bilirubin, albumin, alanine aminotransferase (ALT), aspar-
tate transaminase (AST)] and renal function markers (serum 
creatinine). Estimated glomerular filtration rate (eGFR) 
[18] and creatinine clearance (CrCL) [19] were calculated, 
and demographic information including HIV status was 
obtained from each patient.
2.1  Determination of Cycloserine and Terizidone 
in Plasma
Cycloserine concentration in plasma was determined using 
an ultra-performance liquid chromatography tandem mass 
spectrometry method. Methanol was used to extract cyclo-
serine and propranolol (internal standard) from plasma 
by a protein precipitation method. Acidified acetonitrile 
with 0.1% formic acid was used as the mobile phase, 
and chromatographic separation was achieved on a Phe-
nomenex PFP reversed phase column. The lower limit of 
quantification and limit of detection were 0.01 μg/mL and 
0.004 μg/mL, respectively. The average intra-day precision 
was 10.2%, while inter-day was 7.3%. Accuracy ranged 
between 98.7 and 117.3%, and the coefficient of deter-
mination was 0.9994. Cycloserine was stable after three 
freeze–thaw cycles, and extraction efficiency was in the 
range 88.7–91.2% [20]. Terizidone was analysed using a 
high-performance liquid chromatography with UV detec-
tor (HPLC-UV) method. The within- and between-run 
accuracy was in the range 99.7–112.7% and 100.5–107.4%, 
respectively. The intra- and inter-day precision, measured 
as percentage relative standard deviation, ranged between 
0.35 and 9.4% and 1.48 and 6.79%, respectively. The lower 
limit of quantification was 3.125 µg/mL, while the limit of 
detection was 0.78 µg/mL. The coefficient of determina-
tion value ranged between 0.9988 and 0.9999, and calibra-
tion curves were linear [21].
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2.2  Pharmacokinetic Modelling
The concentration–time profiles of terizidone and its metab-
olite cycloserine were jointly modelled using non-linear 
mixed effects implemented in Monolix 2018R1 software 
[22]. The final joint model without covariates was used to 
estimate the biotransformation rate constant (ktr) describing 
the metabolism of terizidone into cycloserine and cycloser-
ine clearance (CLm/F). The model and the validation details 
have been described elsewhere [16].
2.3  Calculation of the Amount of Cycloserine 
and Other Pharmacokinetic Parameters
The following formulae were coded and added to the Mono-
lix MLXTRAN model script of the final joint model for the 
computation of parameters. The amount of cycloserine was 
calculated as shown in Eq. (1):
where dose is the amount of cycloserine, AUC is the area 
under the concentration–time profile of cycloserine from 0 
to 24 h, and CLm/F is the apparent clearance of cycloserine.
The AUC was calculated by integrating the concentration 
from 0 to 24 h according to Eq. (2):
where C is cycloserine concentration.
Cycloserine half-life was calculated according to Eq. (3):
where ke = (Clm/F)∕10.5.
The distribution volume of cycloserine was fixed to a 
literature value of 10.5 L [11] when estimating CLm/F. 
This was done in order to overcome the non-identifiability 
parameter problem encountered in parent–metabolite phar-
macokinetic models of orally administered drugs [23].
The biotransformation half-life was calculated as shown 
in Eq. (4):
The peak (Cmax) and trough (Cmin) concentrations were 
obtained from the observed data for both cycloserine and 
terizidone concentration–time profiles. The individual 
predicted values for terizidone clearance due to biotrans-
formation (CLtm/F) and other routes (CLto/F) were com-
puted in Monolix and extracted from the output file.
(1)Dose = AUC × Clm/F,
(2)AUC =
24
∫
0
C(t)dt,
(3)Cycloserine half life = ln(2)
ke
,
(4)Biotransformation half-life = ln(2)
ktr
.
2.4  Calculation of Binding Affinity of Unconjugated 
Bilirubin to Albumin and AST/ALT Ratio
The strength of unconjugated bilirubin binding to albumin 
was calculated according to Eq. (5) [24]:
where Kaf is the binding affinity, with the units L/µmol, and 
TB and UB are total bilirubin and unconjugated bilirubin, 
respectively. The AST/ALT ratio [25], a marker reflecting 
alterations in hepatic function, was calculated by dividing 
the AST value by the ALT value for each patient.
2.5  Statistical Analysis
Mann–Whitney U test was performed to determine differ-
ences in the demographic information stratified by HIV 
status. We performed Spearman’s correlations between 
hepatic or renal function (eGFR/CrCL) markers and phar-
macokinetic parameters (Cmin, Cmax, CLm/F, CLtm/F and 
CLto/F). This was done in order to determine whether 
a statistically significant linear relationship existed, as 
cycloserine or terizidone could bind to albumin or affect 
the binding affinity of unconjugated bilirubin to albumin. 
Furthermore, cycloserine concentration may be affected 
by alterations in hepatic or renal function. If the correla-
tions were significant, linear stepwise regression analysis 
was performed in order to determine if pharmacokinetic 
parameters were significantly predicting hepatic or renal 
function markers. A two-tailed p value of ≤ 0.05 was 
considered statistically significant. The analysis was per-
formed in the R version 3.5.3 statistical environment [26].
3  Results
Thirty-nine drug-resistant tuberculosis patients (20 females 
and 19 males) participated in this study. Out of the seven 
patients with comorbidities, three had cryptococcal meningi-
tis, while each of the remaining four had deep venous throm-
bosis, hyperlipidaemia, gastric acid or epilepsy. Thirty-eight 
out of 39 patients took a daily dose of 750 mg terizidone, 
while one patient took 500 mg. Table 1 shows the summary 
of demographic information. The HIV-infected patients had 
significantly lower albumin than their HIV-uninfected coun-
terparts (30 vs. 35.5 g/L; p = 0.041). However, the rest of 
the demographic variables were similar in HIV-infected and 
HIV-uninfected groups.
(5)Kaf =
TB − UB
UB × albumin − TB + UB
,
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3.1  Amount of Cycloserine and Pharmacokinetic 
Parameters
The summary of the calculated amount of cycloserine or 
dose resulting from terizidone metabolism and the values 
for pharmacokinetic parameters is shown in Table 2. There 
was wide variation in cycloserine dose and also in the phar-
macokinetic parameters, except for cycloserine half-life, for 
which the variation was relatively narrow. Table 3 shows the 
summary of terizidone pharmacokinetic parameters. 
3.2  Correlations Between Hepatic Function Markers 
and Pharmacokinetic Parameters of Cycloserine 
and Terizidone
Significant positive correlations existed between AST, ALT, 
conjugated bilirubin, Kaf and cycloserine pharmacokinetic 
parameters (Cmin, Cmax or CLm/F), as shown in Table 4. 
There was significant negative correlation between AST/
ALT ratio and CLm/F (p = 0.016). Meanwhile, there was 
no significant correlation between albumin or unconjugated 
bilirubin and the pharmacokinetic parameters (p > 0.05). 
Similarly, no significant correlations existed between renal 
function markers (CrCL and eGFR) and CLm/F (p > 0.05). 
Significant positive correlations existed between terizidone 
Cmax and conjugated or unconjugated bilirubin (p = 0.038 
and 0.02, respectively), as shown in Table 5.
3.3  Pharmacokinetic Parameters Predictive 
of Hepatic Function Markers
The cycloserine Cmax was found to be a significant predictor 
of both conjugated bilirubin and Kaf, as shown by regression 
plots b and c of Fig. 1. The associations were in such a way 
that an increase in Cmax resulted in a significant increase in 
conjugated bilirubin and Kaf (plot b, β = 0.06, R2 = 22% and 
p = 0.003; plot c, β = 2.3, R2 = 10.1% and p = 0.048). Cmin 
Table 1  Patients’ demographic 
information
ALT alanine aminotransferase, AST aspartate transaminase, BMI body mass index, CrCL creatinine clear-
ance, eGFR estimated glomerular filtration rate, Kaf binding affinity
*Statistically significant
a The values in the column are reported as median and range
Variables HIV infected (n = 27)a HIV uninfected (n = 12)a P value
Age (years) 31 (17–44) 34 (20–56) 0.46
Weight (kg) 51.4 (32.4–64) 50 (39.8–71) 0.69
BMI (kg/m2) 18.5 (12.4–23.5) 17.9 (15–26.1) 0.8
Albumin (g/L) 30 (15–45) 35.5 (26–48) 0.041*
ALT (IU/L) 11 (4–46) 10.5 (4–23) 0.47
AST (IU/L) 36 (20–109) 26.6 (17–76) 0.053
Conjugated bilirubin (µmol/L) 1 (1–8) 1 (1–9) 0.86
Unconjugated bilirubin (µmol/L) 5 (1–17) 7 (2–11) 0.42
Total bilirubin (µmol/L) 6 (2–24) 8 (3–20) 0.69
AST/ALT ratio 3.2 (0.8–8.7) 2.7 (1.9–5.9) 0.39
Kaf (L/µmol) 146 (70.9–710) 128 (75.5–377) 0.84
CrCL (mL/min) 86.4 (34.4–128) 77.8 (55.4–113) 0.41
eGFR (mL/min/1.73 m2) 118 (46–228) 104 (74.9–192) 0.57
Table 2  Cycloserine dose and pharmacokinetic parameters
AUC area under the curve, CLm/F apparent clearance of cycloserine, 
Cmax peak concentration, Cmin trough concentration
Parameter Median (range)
Cycloserine dose (mg) 51.6 (0.64–374)
Cmax (µmol/L) 28.6 (0.49–69.4)
Cmin (µmol/L) 9.1 (0.15–36.3)
AUC (µmol h/L) 201 (3.07–983)
Biotransformation half-life (h) 22.6 (10.2–216)
CLm/F (L/h) 2.6 (0.64–21)
Cycloserine half-life (h) 2.78 (0.34–11.3)
Table 3  Pharmacokinetic parameters for terizidone
CLtm/F terizidone clearance due to biotransformation, CLto/F ter-
izidone clearance via other routes, Cmax peak concentration, Cmin 
trough concentration
Parameter Median (range)
Cmin (µmol/L) 88 (14.3–307)
Cmax (µmol/L) 247 (61–583)
CLtm/F (L/h) 0.29 (0.05–1.14)
CLto/F (L/h) 0.11 (0.035–0.31)
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Table 4  Correlations between 
cycloserine pharmacokinetic 
parameters and liver function 
markers
ALT alanine aminotransferase, AST aspartate transaminase, CLm/F apparent clearance of cycloserine, Cmax 
peak concentration, Cmin trough concentration, Kaf binding affinity, r Spearman’s ρ correlation coefficient
*p < 0.05, **p < 0.001
Cmin (µmol/L) Cmax (µmol/L) CLm/F (L/h)
AST (IU/L) r = 0.26 r = 0.34* r = − 0.06
ALT (IU/L) r = 0.15 r = 0.11 r = 0.35*
Conjugated bilirubin (µmol/L) r = 0.36* r = 0.47** r = 0.07
Unconjugated bilirubin (µmol/L) r = 0.12 r = 0.15 r = 0.09
Kaf (L/µmol) r = 0.38* r = 0.46** r = − 0.02
AST/ALT ratio r = 0.1 r = 0.2 r = − 0.38*
Table 5  Correlations between 
terizidone pharmacokinetic 
parameters and liver function 
markers
ALT alanine aminotransferase, AST aspartate transaminase, CLtm/F terizidone clearance due to biotransfor-
mation, CLto/F terizidone clearance via other routes, Cmax peak concentration, Cmin trough concentration, 
Kaf binding affinity, r Spearman’s ρ correlation coefficient
*p < 0.05
Cmin (µmol/L) Cmax (µmol/L) CLtm/F (L/h) CLto/F (L/h)
AST (IU/L) r = 0.06 r = 0.15 r = − 0.13 r = − 0.06
ALT (IU/L) r = 0.16 r = 0.14 r = 0.1 r = 0.05
Conjugated bilirubin (µmol/L) r = 0.22 r = 0.33* r = 0.13 r = 0.06
Unconjugated bilirubin (µmol/L) r = 0.25 r = 0.37* r = − 0.01 r = − 0.01
Kaf (L/µmol) r = 0.07 r = 0.1 r = − 0.07 r = − 0.15
AST/ALT ratio r = − 0.1 r = − 0.06 r = 0.16 r = − 0.17
Fig. 1  Regression plots of 
cycloserine pharmacokinetic 
parameters predictive of 
conjugated bilirubin, AST/
ALT ratio and Kaf. ALT alanine 
aminotransferase, AST aspartate 
transaminase, Kaf binding 
affinity, CLm/F apparent clear-
ance of cycloserine, Cmax peak 
concentration, Cmin trough 
concentration
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could not significantly predict Kaf in the regression analysis, 
although a significant correlation existed between Cmin and 
Kaf in correlation analysis. Meanwhile, increase in Cmin was 
significantly associated with an increase in conjugated bili-
rubin (plot a, β = 0.1, R2 = 10.6% and p = 0.044). The CLm/F 
significantly predicted AST/ALT ratio, as shown in plot d 
of Fig. 1. Increase in CLm/F was significantly associated 
with a decrease in AST/ALT ratio (β = − 0.2, R2 = 21% and 
p = 0.003). Terizidone Cmax significantly predicted concen-
tration of conjugated bilirubin (β = 0.008, R2 = 14.2% and 
p = 0.018) as well as unconjugated bilirubin (β = 0.012, 
R2 = 11.4% and p = 0.035). The regression plot is shown in 
Fig. 2.
4  Discussion
This study aimed to determine the amount of cycloserine that 
results from the metabolism of terizidone and the relation-
ship between cycloserine exposure parameters and hepatic 
or renal function markers in patients receiving treatment for 
drug-resistant tuberculosis. There appears to be no studies 
in the literature that have quantified the amount of cycloser-
ine as a terizidone metabolite in drug-resistant tuberculosis 
patients. Terizidone is thought to undergo complete hydroly-
sis into cycloserine pre-systemically [7]. Since one mole 
of terizidone has two moles of cycloserine and a mole of 
terephthalaldehyde moiety, it is expected for a 750-mg daily 
dose of terizidone to produce 507 mg of cycloserine, with an 
assumption that bioavailability is near 100%. In the current 
study, the median dose of cycloserine produced from a 750-
mg dose of terizidone was 51.6 mg, which was lower than 
expected. This observation clearly suggests that terizidone 
is not completely hydrolysed to cycloserine pre-systemically. 
Furthermore, terizidone was detected systemically over a 
period of 24 h after its administration, and on average, only 
29% of the total dose was metabolised to cycloserine [16]. 
The clinical implication of this finding in the current study 
is that cycloserine and terizidone should not be used inter-
changeably, as exposure parameters (Cmax, Cmin and AUC) 
may be significantly lower in patients taking terizidone 
than those taking cycloserine. Owing to the low amount of 
cycloserine produced from terizidone, dose optimisation or 
therapeutic drug monitoring, contrary to what some authors 
imply [27], should be based on terizidone and not cyclo-
serine concentration. Additionally, in patients treated with 
terizidone, Court et al. [28] reported higher cycloserine Cmax 
than in the current study. The difference could have been that 
in the Court et al. study [28], there were patients who had 
renal insufficiency, which could have led to accumulation 
of cycloserine, as it primarily undergoes renal elimination 
[6]. Furthermore, the bioavailability and biotransformation 
rate of terizidone into cycloserine in the current study could 
have been lower than in the Court et al. [28] study. We can-
not overlook the possibility of pharmacokinetic interactions 
with co-administered drugs in the current study.
Bilirubin, a pigment derived from the breakdown of 
haemoglobin, increases in blood because of an imbalance 
between its production and excretion. Since unconjugated 
bilirubin is not water soluble, it is bound to albumin and 
transported to the liver, where it is made soluble or conju-
gated with glucuronic acid and subsequently undergoes bil-
iary excretion into the gastrointestinal tract [29]. Increased 
serum levels of conjugated bilirubin are an indication of 
hepatic dysfunction or liver disease, clinically manifested as 
jaundice [25]. In the current study, cycloserine Cmin and Cmax 
as well as terizidone Cmax were significantly associated with 
increased concentration of conjugated bilirubin.
Although the concentration of conjugated bilirubin in 
most of the patients was within the normal range, this obser-
vation implies that high plasma cycloserine or terizidone 
concentrations may be associated with hyperbilirubinaemia 
in some patients.
Fig. 2  Regression plots of ter-
izidone pharmacokinetic param-
eters predictive of conjugated 
and unconjugated bilirubin. 
Cmax peak concentration
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Unconjugated bilirubin is insoluble in water and hence 
cannot be excreted via the kidney. It is instead bound to albu-
min and transported to the liver for conjugation. Increased 
serum levels of unconjugated bilirubin indicate that there 
is an accumulation in the bloodstream due to haemolysis, 
which may be caused by haemolytic anaemia, hepatocel-
lular dysfunction (e.g. hepatitis) and cirrhosis in which the 
excretory function of the hepatocytes is impaired [25]. Some 
drugs have been shown to compete with unconjugated biliru-
bin for binding to albumin, which leads to increased concen-
tration of unconjugated bilirubin and causes encephalopa-
thy in neonates [30–33]. Therefore, the binding affinity of 
unconjugated bilirubin to albumin is of clinical importance. 
Cycloserine Cmax in the current study was associated with 
increased Kaf, while Cmin results were insignificant. This 
means that high cycloserine concentrations improve the 
binding affinity of unconjugated bilirubin to albumin, which 
is potentially a desired characteristic in bilirubin metabo-
lism. The observed relationship between Kaf and Cmax may 
also imply that cycloserine is less bound to albumin.
The AST/ALT ratio is a non-invasive diagnostic index 
used to predict liver cirrhosis or fibrosis, and a value higher 
than 1 is indicative of non-alcoholic fatty liver disease [34, 
35]. Cycloserine is primarily renally cleared, with 70% 
excreted unchanged [12], while the other portion is metabo-
lised in the liver. However, the enzymes specifically involved 
in the catabolism of cycloserine in vivo are not known. In 
the current study, higher CLm/F was significantly associated 
with low AST/ALT ratio. Additionally, the median value 
of the AST/ALT ratio was more than 2. This was an obvi-
ous indication that liver disease affects hepatic function, 
which leads to low activity or production of cycloserine-
metabolising enzymes and eventually results in low CLm/F. 
Meanwhile, the non-correlation between CLm/F and CrCL 
or eGFR in the current study was unexpected, as cycloserine 
is also cleared via the renal route. This observation could 
suggest a possibility of more cycloserine undergoing active 
tubular secretion than glomerular filtration, as seen in other 
drugs [36].
This study has some limitations to consider. In vitro drug 
plasma binding studies were not performed due to ethical 
issues as we were supposed to use drug-free human plasma. 
Cycloserine metabolites were not measured in plasma; 
this could have helped to determine the rate of cycloser-
ine metabolism in vivo. Furthermore, cycloserine was not 
measured in patients’ urine for determination of the fraction 
of the dose that is excreted unchanged. We only measured 
cycloserine and terizidone in plasma. Since patients were 
on a multidrug treatment regimen, other anti-tuberculosis 
drugs could have shown similar results as cycloserine and 
terizidone. The study, however, is important as it gives an 
insight into how cycloserine and terizidone exposure might 
affect hepatic function. This can guide the clinical decision 
regarding whether or not to withdraw terizidone in the case 
of hepatotoxicity.
5  Conclusions
In conclusion, the amount of cycloserine resulting from 
the metabolism of terizidone in drug-resistant tuberculosis 
patients was lower than expected. High concentrations of 
cycloserine could potentially favour bilirubin disposition, 
albeit be a predisposing factor to the development of jaun-
dice in drug-resistant tuberculosis patients taking terizidone. 
Cycloserine clearance is reduced in hepatic dysfunction.
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Chapter Eight 
 
8.0 INTRODUCTION 
In this chapter, a brief general discussion of important findings from chapter four, five, 
six and seven are presented. These findings are with regard to the developed methods 
for bioanalysis of terizidone and cycloserine in plasma. Other findings concern the 
population pharmacokinetics of terizidone and cycloserine as well as the use of 
cyloserine and terizidone interchangeably. Otherwise, the detailed discussion has 
already been outlined in these chapters. 
8.1 Quantification of terizidone in plasma 
There appears to be only one method in literature in which terizidone was quantified 
in plasma (Zitkova and Toušek, 1974) using colorimetric method (Jones, 1956). In this 
method, terizidone was not measured directly but estimated based on its metabolite 
cycloserine. The principle behind colorimetric method is the measurement of optical 
absorbance of a coloured reaction product between analyte and suitable reagents 
using light (Benhabib and Li, 2013). Colorimetric method of analysis is not suitable for 
pharmacokinetic studies as interfering substances can produce similar colours and 
cause errors in the results (Armstrong and Kuder, 1935). Furthermore, colorimetric 
method is outdated (World Health Organization, 2018). Additionally, in colorimetry, 
different compounds exhibit variances that can affect the accuracy of the results 
(Scott, 2017). Chromatographic methods are commonly used in pharmacokinetic 
studies as they are the most versatile bioanalytical techniques and able to produce 
highly accurate and precise results (USFDA, 1999, ICH). In Chapter four (Mulubwa 
and Mugabo, 2018), a chromatographic method (HPLC-UV) for determination of 
terizidone in plasma was developed and validated. This was the first-ever 
chromatographic method to be developed for analysis of terizidone. In this developed 
method (Mulubwa and Mugabo, 2018), terizidone was accurately quantified unlike in 
the colorimetric method where it was estimated based on cycloserine (Jones, 1956). 
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In Chapter four (Mulubwa and Mugabo, 2018), terizidone was detected and quantified 
in patients’ plasma samples. However, this was contrary to the proposition by the 
World Health Organization that terizidone is not measurable in plasma as it is thought 
to hydrolyse completely into cycloserine pre-systemically (World Health Organization, 
2015). The proposition was based on the fact that there were no analytical methods in 
literature in which terizidone was directly measured in plasma and not estimated based 
on its primary metabolite cycloserine. Therefore, this proposition no longer holds 
because terizidone is measurable in plasma. 
8.2 Quantification of cycloserine in plasma 
There are several bioanalytical methods that have been described in literature for the 
determination of cycloserine in plasma using liquid chromatograph coupled to mass 
spectrometer (Polagani et al., 2013, Patel et al., 2011, Mao et al., 2017, Yaroshenko 
et al., 2014, Han et al., 2013). The aim of Chapter five was to develop a method that 
involved less steps in sample preparation and sensitive or ability to measure lower 
concentrations than those reported in literature with good accuracy and precision. The 
developed method in Chapter five (Mulubwa and Mugabo, 2019a) had relatively less 
steps in sample preparation than the previously reported methods (Han et al., 2013, 
Supriya et al., 2012). Furthermore, the method (Mulubwa and Mugabo, 2019a) was 
more sensitive (0.01 µg/mL vs. 0.05 µg/mL) than the previously reported (Polagani et 
al., 2013). The method was suitable for bioanalysis especially where cycloserine is 
expected to be in very low concentrations as terizidone metabolite.  
8.3 Pharmacokinetics of terizidone and cycloserine 
The aim of Chapter six (Mulubwa and Mugabo, 2019b) was to model the 
pharmacokinetics of terizidone and cycloserine and to determine the factors that affect 
the pharmacokinetics of these drugs. A one-compartment model with first-order 
elimination best described the pharmacokinetics of terizidone. A modified transit 
compartment model characterised well the absorption of terizidone. Cycloserine 
underwent first order elimination with a shorter half-life than terizidone. Terizidone’s 
long half-life implies that it can be dosed once daily and still achieve the desired 
plasma concentration although the target Cmax or AUC is still unknown. 
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The clearance of terizidone via biotransformation is higher than clearance via other 
routes. This finding has clinical implications in patients who may have reduced hepatic 
function due to liver disease. Although the enzymes involved in terizidone metabolism 
are not known, patients with liver disease may experience toxic effects as a result of 
accumulation of terizidone in plasma due to reduced hepatic clearance. The inverse 
relationship between terizidone distribution volume and albumin may have clinical 
implications. It may imply that in patients with low albumin concentration due to a liver 
disease, the exposure pharmacokinetic parameters such as Cmax and Cmin may reduce 
due to an increase in terizidone distribution volume. This has potential to cause 
resistance owing to low plasma drug exposure. 
The fraction of the total amount of terizidone in the body that was converted to 
cycloserine, on average was 29% (Mulubwa and Mugabo, 2019b). This observation 
clarifies the contrary view of the World Health Organization that terizidone is near 
complete (World Health Organization, 2018) or completely converted into cycloserine 
(World Health Organization, 2015). 
8.4 Cycloserine amount resulting from terizidone metabolism 
The objective of Chapter seven was first to determine the amount of cycloserine that 
emanates from the metabolism of terizidone in patients with drug-resistant 
tuberculosis. The second objective was to determine the relationship between the 
cycloserine pharmacokinetic parameters and markers of hepatic or renal function. The 
average amount of cycloserine that emanated from terizidone metabolism was far less 
than the expected theoretical amount. This means that terizidone and cycloserine are 
not equivalent. The clinical implication is that they should not be used interchangeably 
as exposure parameters such as Cmax, Cmin and AUC may be lower in patients taking 
terizidone than those taking cycloserine.  
The ratio of aspartate transaminase to alanine aminotransferase, which relates to non-
alcoholic fatty liver disease (Alexopoulou et al., 2019, Angulo, 2002), was inversely 
related to cycloserine clearance. This indicated that cycloserine was affected by 
hepatic function and implied that it was cleared by the liver in addition to the known 
renal clearance (Brennan et al., 2008). Meanwhile, the non-significant relationship 
between exposure parameters (Cmax and Cmin) and markers of renal function 
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(estimated glomerular filtration rate and creatinine clearance) implied that cycloserine 
was not freely filtered but secreted in renal tubules. High cycloserine concentrations 
promoted disposition of unconjugated bilirubin by increasing its binding affinity to 
albumin in order to transport it to the liver for conjugation and subsequent elimination 
into the bile. However, cycloserine concentration was significantly associated with 
increased concentration of conjugated bilirubin. The clinical implication of this 
observation is that cycloserine may be associated with hyperbilirubinemia as a side 
effect in some patients as conjugated bilirubin is what is responsible for the clinical 
signs of jaundice (Longo et al., 2013).  
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Chapter Nine 
 
9.0 STUDY OBJECTIVES ACCOMPLISHED  
In this non-randomised clinical study, 39 patients with drug-resistant tuberculosis and 
in intensive treatment phase were prospectively enrolled at Brewelskloof Hospital in 
South Africa. All of the objectives set out in Chapter one were successfully achieved. 
These objectives included: 
i. the development and validation of a high-performance liquid 
chromatography method coupled with ultraviolet detection (HPLC-UV) for 
determination of terizidone in plasma, 
ii. the development and validation of a sensitive ultra-performance liquid 
chromatography tandem mass spectrometry (UPLC-MS/MS) method for 
determination of cycloserine in plasma,  
iii. the determination of plasma concentrations of terizidone and cycloserine 
in patients with drug-resistant tuberculosis, 
iv. modelling population pharmacokinetics of terizidone and its metabolite 
cycloserine in patients with drug-resistant tuberculosis, 
v. the determination of the factors influencing pharmacokinetics of terizidone 
and cycloserine in patients with drug-resistant tuberculosis,  
vi. the determination of the amount of cycloserine emanating from terizidone 
metabolism in patients with drug-resistant tuberculosis. 
 9.1 OVERALL CONCLUSIONS  
The bioanalytical method (HPLC-UV) for the determination of terizidone in plasma for 
pharmacokinetic study was successfully developed, validated and applied in the 
analysis of patients’ plasma samples. The method was simple, accurate and precise 
making it also suitable for therapeutic drug monitoring of terizidone. The UPLC-MS/MS 
bioanalytical method for determination of cycloserine in plasma was developed and 
validated. The method was sensitive or able to measure very low concentrations of 
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cycloserine with acceptable accuracy and precision. The method was successfully 
used to measure cycloserine as terizidone metabolite in patients’ plasma samples. 
The population pharmacokinetic of terizidone and cycloserine, has for the first time, 
been described in patients with drug-resistant tuberculosis. A one-compartment model 
with first-order elimination process best describes the pharmacokinetics of terizidone 
in drug-resistant tuberculosis patients. A modified transit model best characterises its 
absorption process. About 29% of the total amount of terizidone in the body is 
metabolised into cycloserine and undergoes first-order elimination process. The 
apparent distribution volume of terizidone in drug-resistant patients is influenced by 
albumin concentration, which may affect drug concentration in patients with hepatic 
impairment. Terizidone and cycloserine cannot be used interchangeably as the 
amount of cycloserine emanating from metabolism of terizidone is far lower than 
expected. Cycloserine plasma exposure may be a predisposing factor to development 
of jaundice because of its relationship with conjugated bilirubin and its apparent 
clearance is reduced in patients with non-alcoholic fat liver disease. 
9.2 STUDY LIMITATIONS  
This study addressed only the pharmacokinetics of terizidone and its metabolite 
cycloserine. The pharmacodynamics part, which needed to establish the minimum 
inhibitory concentration (MIC) of terizidone, was not performed. Consequently, the 
Monte Carlo simulations for terizidone dose optimization in this population of patients 
were not carried out.  
The concentrations of both terizidone and cycloserine were not measured in urine. 
This information would have helped to determine the amount of each drug eliminated 
in unchanged form. The sample size in this study was not calculated due to lack of a 
population pharmacokinetic model of terizidone in literature, which could have been 
used to simulate and estimate the required patient sample size. 
9.3 RECOMMENDATIONS 
The MIC of terizidone in resistant strains of Mycobacteria tuberculosis needs to be 
determined in order to establish pharmacodynamic index for dosage optimisation in 
drug-resistant tuberculosis patients. Furthermore, suitable pharmacodynamic indices 
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such as Cmax/MIC (Blaser et al., 1987, Preston et al., 1998), AUC/MIC (Holmes et al., 
2013, Ramos-Martin et al., 2017, Zinner et al., 2001) or percentage of time that plasma 
concentration remains above MIC (%T> MIC) (Andes et al., 2003, McKinnon et al., 
2008) for terizidone need to be determined. 
Based on low clearance and long half-life, terizidone should be dosed once daily. The 
dosing should not be same as that of cycloserine but should be based on the 
appropriate pharmacodynamics index. Although albumin was significantly affecting 
the distribution volume of terizidone, the clinical significance of this needs to be 
evaluated and establish whether dose adjustment is necessary. Future studies should 
determine the amount of terizidone and cycloserine excreted in patients’ urine. Finally, 
the sample size for future terizidone pharmacokinetics studies can be estimated from 
the model developed in this thesis.  
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DESCRIPTION: 
AUC computation of parent and metabolite for 1-compartment 
model with first-order absorption and elimination with 
parameters Mtt, ka, Vp, Cl, Fm and Clm using Ordinary 
Differential Equations. 
 
[LONGITUDINAL] 
input = {Mtt, ka, Vp, Cl, Fm, Clm} 
 
PK: 
depot(target = Ad, Mtt, Ktr = ka, ka) 
 
EQUATION: 
odeType = stiff 
Vm = 10.5     
kp = Cl/(Vp*(1-Fm))   
kt = Cl/(Vp*Fm)    
km = Clm/Vm    
 
;Initial conditions 
t_0 = -120 
Ad_0 = 0 
Apc_0 = 0     
Am_0 = 0     
 
;Differential equations 
ddt_Ad = -ka*Ad 
ddt_Apc = ka*Ad - kp*Apc - kt*Apc  
ddt_Am = kt*Apc - km*Am 
ddt_AUCp = 1/Vp * Apc 
ddt_AUCm = 1/Vm * Am 
 
 
if(t < 24) 
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     AUC24p = AUCp 
end 
if(t < 48) 
     AUC48p = AUCp 
end 
AUC24_48p = AUC48p - AUC24p  
if(t < 24) 
     AUC24m = AUCm 
end 
if(t < 48) 
     AUC48m = AUCm 
end 
AUC24_48m = AUC48m - AUC24m  
 
;other PK parameters 
T_HalfTZ = log(2)/(kp + kt)    
T_HalfCS = log(2)/km     
Cl_TZtrans = kt*Vp      
Cp = Apc/Vp      
Cm = Am/Vm      
 
OUTPUT: 
output = {Cp, Cm} 
table = {AUC24_48p, AUC24_48m, T_HalfTZ, T_HalfCS, Cl_TZtrans} 
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OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
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BY YOU. 
WILEY shall have the right to terminate this Agreement immediately upon breach of
this Agreement by you.
You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach
of this Agreement by you.
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE,
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER
OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN. 
Should any provision of this Agreement be held by a court of competent jurisdiction
to be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this Agreement
shall not be affected or impaired thereby. 
The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition
of this Agreement. No breach under this agreement shall be deemed waived or
excused by either party unless such waiver or consent is in writing signed by the party
granting such waiver or consent. The waiver by or consent of a party to a breach of
any provision of this Agreement shall not operate or be construed as a waiver of or
consent to any other or subsequent breach by such other party. 
This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
Any fee required for this permission shall be non-refundable after thirty (30) days
from receipt by the CCC.
These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes
all prior agreements and representations of the parties, oral or written. This Agreement
may not be amended except in writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives,
and authorized assigns. 
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In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
these terms and conditions shall prevail.
WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms
and conditions.
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.
This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state's conflict of law rules. Any
legal action, suit or proceeding arising out of or relating to these Terms and Conditions
or the breach thereof shall be instituted in a court of competent jurisdiction in New
York County in the State of New York in the United States of America and each party
hereby consents and submits to the personal jurisdiction of such court, waives any
objection to venue in such court and consents to service of process by registered or
certified mail, return receipt requested, at the last known address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
Creative Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and non-
Creative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online Library
http://olabout.wiley.com/WileyCDA/Section/id-410895.html
Other Terms and Conditions:
v1.10 Last updated September 2015
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Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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